proposed programme and budget...

Scientific Council SC/53/9 Rev.1 Fifty-third Session 19/01/2017 Lyon, 25–27 January 2017 Auditorium

PROPOSED PROGRAMME AND BUDGET 2018–2019

(Revision 1)

[Page intentionally left blank]

i

TABLE OF CONTENTS

1. INTRODUCTION 1

2. THE IARC PROGRAMME 2018–2019 5

Objective 1 Describe the occurrence of cancer 5

Objective 2 Understand the causes of cancer 6

Objective 3 Evaluate and implement cancer prevention and control strategies 8

Objective 4 Increase the capacity for cancer research 9

Objective 5 Provide strategic leadership and enhance the impact of the Agency’s contribution to global cancer research 11

Objective 6 Enable and support the efficient conduct and coordination of research 13

3. PROPOSED BUDGET 2018–2019 14

3.1 Explanation of the proposed regular budget 14

3.2 Financing of the regular budget 16

3.3 Extrabudgetary resources 17

4. BUDGET TABLES 21

A Proposed regular budget for the biennium 2018–2019 23

B Summary of biennial resources by level 2/3 objectives and sources of fund 24

C Summary of regular budget by level 2/3 objectives and year 25

D Summary of regular budget funded staff by level 2/3 objectives and staff category 26

E Analysis of staffing and resources by level 2/3 objectives 27

F Summary of budget changes from previous biennial budget 28

G Summary of regular budget by component and cause of increase/decrease 29

H Summary of regular budget and proposed financing 30

I Summary of proposed financing from assessments on Participating States and Governing Council Special Fund 31

ANNEXES 33

Information Table A Total staff and non-staff budget by Section and Group 35

Information Table B United Nations accounting rates of exchange: euros to US dollars 36

Information Table C IARC Project Tree structure and associated projects 37

Information Table D Group classification of countries and assigning units for assessed contributions 39

Information Table E Comparison of assessments on Participating States based on current and revised scales 40

Information Table F Comparison of proposed regular budget 2018–2019 with approved regular budget 2016–2017 by level 2/3 objectives 41

Information Table G Priority projects requiring additional voluntary contributions 42

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 1 1. INTRODUCTION

The Proposed Programme and Budget 2018–2019 reflects the priorities set out in the IARC Medium-Term Strategy 2016–2020 (MTS) (GC/57/7) adopted by the Governing Council (resolution GC/57/R8). As with the previous Programme and Budget, the present document is structured according to the ‘IARC Project Tree’ (Information Table C), a framework showing how IARC’s activities at project level contribute to achieving the strategic goals defined in the MTS.

The use of a common integrated structure to present strategy, programme and budget permits a clear understanding of how IARC’s strategic priorities are being addressed, of the relative balance between different areas of activity, and of the corresponding decisions in terms of resource allocation.

Based on the priority objectives set out in the IARC Project Tree the work of the Agency is centred on six core areas:

1 - Describe the occurrence of cancer 2 - Understand the causes of cancer 3 - Evaluate and implement cancer prevention and control strategies 4 - Increase the capacity for cancer research 5 - Provide strategic leadership and enhance the impact of the Agency’s contribution to global

cancer research 6 - Enable and support the efficient conduct and coordination of research

The details of the strategy and activities in these priority areas for each of the IARC Sections and Groups is set out in the MTS and its associated Implementation Plans, respectively. In the following sections, the main objectives of the programme are outlined for each of the six core areas, which involve projects led by different Sections and Groups. The objectives, activities and budget of each individual project were defined in Project and Budget Proposal Sheets, submitted to review by the Scientific Council, which were mapped to the Project Tree structure. Resource allocations are presented at level 2 and 3 objectives of the Project Tree, thus permitting comparisons with the previous biennial budget 2016–2017 (Information Table F).

IARC appreciates the challenges faced by individual Participating States in approving the assessed contributions comprising the regular budget. The Agency has therefore prepared the proposed Programme and Budget 2018–2019 with a view to maintaining the same level of programmatic activity as in 2016–2017, with minimal change in the number of staff. Nevertheless, in order to meet evolving needs, the proposal reflects the abolition of some Sections and Groups as well as restructuring across a number of areas. This has necessitated considerable change management within a dynamic environment of both increasing opportunities and resource constraints. The impacts of these decisions on the budget are highlighted in the current document under each of the six priority objectives of the Project Tree.

The successful implementation of the IARC MTS can be achieved only through an integrated budget which complements the regular budget with extrabudgetary funds coming from competitive grant applications and a variety of other sources. The balance between these different funding sources is described briefly below.

http://governance.iarc.fr/GC/GC57/En/Docs/GC57_7.pdf

http://governance.iarc.fr/GC/GC57/En/Docs/GC57_ResolutionsR1_R21.pdf

SC/53/9 Rev.1 Scientific Council Page 2 Proposed Programme and Budget 2018–2019 (Revision 1)

Over the last decade (2008–2009 onwards), staff costs - mainly statutory - have increased by close to €10 million, a 40% rise (Figure 1). Over the same period, the Governing Council has adopted an approach of zero nominal growth in assessed contributions from existing Participating States. However, to offset the major increase in staff costs, the Governing Council has agreed to increase biennial budgets through the assessed contributions from new Participating States joining IARC and, in the last three biennia, also through the use of supplementary funds from the Governing Council Special Fund (GCSF) (Figure 2).

Figure 1: Staff budget, non-staff budget, and number of posts

Figure 2: Approved regular budget 2008–2017 and proposed budget 2018–2019

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 3 To further offset the rising staff costs, the non-staff budget has also been reduced, remaining €2.1 million lower in absolute terms in the Proposed Programme and Budget 2018–2019 than in 2010–2011 (Figure 1). The proportion of regular budget allocated to general management and administrative services has also been decreasing since 2010. This is largely the result of a sustained and carefully balanced effort to further improve the efficiency of services, while aiming to prioritize investment in the scientific programme.

The above approach to maintaining programmatic activity consistent with successful delivery of the IARC MTS presents some risks. First, there is an expectation from new Participating States of an increased scope in the Agency’s programme which must be managed without an increase in resources in real-terms. Indeed, expectation is also widespread among many additional stakeholders as the global importance of cancer within the broader noncommunicable disease agenda becomes increasingly clear. Second, the reliance on GCSF to fund the regular budget (€1.0 million in 2012–2013 and €0.5 million in each of the two subsequent biennia) is unlikely to be sustainable, particularly given the demands over the last decade on the GCSF to fund core elements of infrastructure, including laboratory equipment, biobank facilities and computing software and hardware as well as required improvements in security measures. This approach relies on continued income to the GCSF that is not secured. Notably there is a forecasted drop in income over the next biennium because of the completion of the 10-year period of payment of arrears from the Russian Federation. The additional sum currently funded from GCSF for the 2016–2017 biennium represents an average of €20 000 per Participating State. In this light, the Secretariat proposes the 2018–2019 regular budget to be financed only by assessed contributions from Participating States.

To ensure achievement of the required level of programmatic activity, the Agency has financed an increasing number of staff positions from alternative sources (Figure 3). Notably an increased number of posts have been financed from Programme Support Costs (PSC) generated from overheads on research grants, from GCSF generated from sales of publications, or from unbudgeted assessments from new Participating States (UB). At the time of preparation of the proposed Programme and Budget 2018–2019, 11.8 posts are anticipated to be financed from PSC in 2018–2019, 8 posts from GCSF and 5 posts from UB (Figure 3).

Figure 3: Number of posts funded from PSC, GCSF and UB in 2010–2019


The PSC is used for positions in the Section of Support to Research (including in finance, procurement, IT and HR). The GCSF is used mainly for positions to ensure IARC publications, including in the Monographs Section (a pathologist, project assistant, clerks for production of the WHO Classification of Tumours series) and the Communications Group (publishing assistant, editor, web design, and social media). In contrast, the UB are used to support key scientific areas, prioritized in response to Scientific Council reviews (e.g. bioinformatics). Some of the support posts financed on PSC would be reduced if the scale of activity based on voluntary contributions from research grants were to drop. However, it is noteworthy that a number of essential positions are funded outside of the regular budget including a finance assistant, a budget assistant, IT helpdesk, and central secretarial pool.

The Agency has been successful in generating voluntary contributions to complement and build upon the platform provided by the regular budget, using the former funds to support an increased number of research posts (Professional and General Service). The extrabudgetary funds already secured for the 2018–2019 period are included in the integrated budget shown in budget tables; it is a signal of the strong performance of the Agency that the extrabudgetary resources secured at the time of preparing the previous Programme and Budget 2016–2017 were €8.2 million, compared to €16.4 million at the time of the current planning for 2018–2019, i.e. an additional €8.2 million or 100% increase across the two biennia.

As a new feature in the presentation of the Proposed Programme and Budget 2018–2019, the Agency has identified a number of discrete high priority projects for which extrabudgetary resources have not yet been secured. These projects will be the focus of specific resource mobilization efforts. The projects are detailed in the Information Table G and are presented to permit individual Participating States to consider making additional voluntary or in-kind contributions targeted to these project areas.

In summary, the Secretariat will continue to use all available resource streams to deliver the Programme and thus to fulfil the MTS. In line with the principles of maintaining the same level of programmatic activity, of minimal change to staffing levels and ceasing the reliance on the GCSF, the overall level of the proposed regular budget from assessed contributions, total €45.07 million, is based on the approved budget figures for 2016–2017 supplemented with the full contribution from Morocco plus an increase of just under €0.9 million in assessed contributions from the other 24 Participating States (an increase of 2.09%). This proposed budget represents a 3.82% increase from the approved 2016–2017 biennial budget. A combination of this regular budget and anticipated voluntary contributions will enable the continued successful delivery of the IARC MTS 2016–2020.

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 5 2. THE IARC PROGRAMME 2018–2019

Objective 1 - Describe the occurrence of cancer

Monitoring global cancer occurrence, provision of accurate and timely statistics at national, regional and global level, and descriptive epidemiology remain core activities. Reliable cancer statistics are an essential component of effective cancer control programming, through identifying priorities for action and subsequently providing data for monitoring and evaluation of specific interventions. Recognizing the context of cancer within the broader noncommunicable disease (NCD) agenda, the Agency is also assessing the cancer burden relative to other NCDs, with expansion into new areas of expertise, notably demography (for gains in life expectancy), and economics (in relation to costs due to lost productivity).

Research in this area focusses on novel analyses of geographical, temporal and socioeconomic cancer patterns, highlighting the changing profiles and scale of cancer burden worldwide. The Agency does not only collate and analyse cancer statistics but also works alongside colleagues in cancer registries nationally to improve the quality and coverage of cancer registration worldwide.

Improved access to these data, in the sense of shared “public goods”, has driven the development of the new IARC Global Cancer Observatory, which encompasses available data on cancer burden in adults and children as well as on cancer risk factors and their impact by country worldwide.

Another important activity under this objective is production of the ‘WHO Classification of Tumours’ series, representing the consensus on tumour classification among international experts in cancer pathology. The revisions of the so-called “Blue Books” incorporate new disease entities and represent the international reference in human tumour classification. This is an essential provision for cancer surveillance, for epidemiological research and more broadly for the effective clinical management of cancer.

The main objectives in this area from the IARC Project Tree are therefore:

a. to improve and expand the reporting of descriptive cancer statistics;

b. to support improved coverage and quality of cancer registration, particularly in low- and middle-income countries (LMIC);

c. to improve tumour classification to inform cancer registration, research and treatment.

The Section of Cancer Surveillance (CSU) has a primary focus on this objective, with further contributions from the Sections of Nutrition and Metabolism (NME), Infections (INF) and Early Detection and Prevention (EDP). The Blue Books Group (BLB) within the Section of IARC Monographs (IMO) is responsible for the publications on tumour classification.

The overall resource level attributed to areas (a) and (b) above has been slightly increased from the 2016–2017 budget. However, within this largely unchanged overall budget there has been additional restructuring in response to the changing demands on CSU, notably the need to effectively manage additional personnel funded by extrabudgetary funds, for example in the context of the Global Initiative on Cancer Registration (GICR).

A significant reorganization occurred in area (c). The Molecular Pathology (MPA) Section had responsibility for the WHO Classification of Tumours project in addition to conducting a research


programme on brain cancer. With the retirement of the Section Head a decision was taken to abolish the Section to permit two major changes: first, to consolidate laboratory research into fewer Groups/Sections, and second, to integrate the WHO Classification of Tumours project with the IARC Monographs and IARC Handbooks of Cancer Prevention in one Section. In addition to placing scientific and support staff in the same IMO Section, other personnel involved in the publishing process (notably editing and layout) from both MPA and IMO have been transferred into an expanded Communications Group (COM) to achieve efficiencies and economies of scale.

This major restructuring enhances scientific synergies across these three flagship publications, supports the adoption of best practices in expert evaluation and publishing processes and will yield economies of scale. In addition, the abolition of one research Section is a necessary response to the budgetary constraints faced by the Agency, permitting the non-staff budget to be maintained across the remaining Sections and some reinvestment in specific priority areas (e.g. bioinformatics). The Agency will be comprised of eight rather than nine research Sections.

The assignment of the Head, BLB full-time to the WHO Classification of Tumours project, together with reallocation of some additional support staff, has led to an increase in resources assigned to area (c). The combination of the above-mentioned changes across Objective 1 has led to a small increase in the overall proportion of the regular budget assigned to this area from 7.30% to 7.78%.

Objective 2 - Understand the causes of cancer

The causes of a significant proportion of common human cancers remain unknown. Research into preventive interventions requires an understanding of underlying etiology. Therefore a significant effort continues to be placed by the Agency on studying the interaction between environmental, lifestyle and genetic factors on the development of human cancers, drawing on unique opportunities for collaborative work worldwide.

Emphasis is placed on cancers of importance in LMICs and on interdisciplinary research. An interdisciplinary approach allows vital mechanistic insights into the biological plausibility of risk-factor/disease associations from epidemiologic studies, and the development and validation of new biomarkers for exposure assessment, susceptibility, early detection and prognosis of cancer. The knowledge gained through research on cancer causes is a foundation to investigation of strategies for cancer prevention and early detection, as addressed in Objective 3.

In addition to original research in this area, the Agency conducts international expert evaluations of the published scientific evidence on the carcinogenicity of potential risk factors. The IARC Monographs programme is widely regarded as the international reference in cancer hazard identification, used extensively by national and international risk assessment agencies to develop policies for cancer prevention by reducing exposure to known and suspected carcinogens. Dissemination of findings will be further enhanced with the development of a user-friendly and searchable internet database of Monographs, interlinked with other databases hosted at IARC (e.g. WHO ‘Blue Books’, Global Cancer Observatory, Handbooks of Cancer Prevention) and externally (e.g. ICD-11, PubChem).

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 7 Major contributions to Objective 2 are made by INF, NME, IMO, Environment and Radiation (ENV), Genetics (GEN) and Mechanisms of Carcinogenesis (MCA) Sections, with further contributions from CSU. Specifically, CSU collaborates with different Sections to combine information on risk factors and cancer burden in order to provide global, regional or national estimates of the Population Attributable Fraction of cancers associated with a specific exposure. Such estimates are a further valuable support to cancer control planning worldwide.

The aims of the three broad categories of projects in this area are therefore:

a. to elucidate the contribution of different risk factors to cancer causation, through the conduct of epidemiologic studies;

b. to characterize the cellular and molecular changes induced by cancer risk factors, elucidating the underlying mechanisms of carcinogenesis and providing biomarkers for application to epidemiologic studies;

c. to provide authoritative, independent evaluations of the carcinogenic potential of environmental, lifestyle, and occupational factors of public health importance.

This area continues to represent a major focus for IARC with 26.34% of the overall budget, including a majority of the laboratory-based research. Within this overall figure there are, however, noteworthy trends and changes. The allocation to Objective 2 has decreased from 30.38% in 2014–2015 to the current level for 2018–2019, representing a reduction of around €1.3 million in absolute terms over three successive budget periods. This reflects the change in balance between the continued need for research on causes, under Objective 2, and for research more immediately relevant to policy application, conducted under Objectives 1 and 3.

In this context there has been recognition by IARC’s governing bodies of the importance of providing regular budget support to the Monographs (area (c) above) in order to reduce the risks related to heavy reliance on extrabudgetary resources. The modest increase in personnel assigned to the Monographs in the 2016–2017 regular budget has been complemented in the current proposed budget 2018–2019 by an additional €123 000 in non-pay budget. Without these changes to area (c) the decrease in the overall budget assignment to Objective 2 would have been greater.

The interdisciplinary work on cancer causation increasingly draws on large complex datasets with demands in terms of both biostatistics and bioinformatics. Bioinformatics has been highlighted by the Scientific Council, successive Peer Review Panels and by the Governing Council in May 2016 as an area where the Agency needs to ensure sufficient resources for its evolving programme, both in personnel and high performance computing (HPC) and data storage capacity. The Agency has made additional resources available in a combination of ways. First, a reduction in secretarial support to the MCA Section and discontinuation of the MPA Section has permitted creation of a new support post in bioinformatics (MCA) and a new computational biologist scientist post (Biomarkers Group, BMA). Second, additional required posts in bioinformatics have been funded through use of UB. Third, existing staff have changed duties to encompass bioinformatics activities. Fourth, a full review of computing needs has led to a proposal to the Governing Council for use of GCSF to finance the expanded HPC and data storage requirements.


Thus the above changes in bioinformatics capacity have been achieved within the overall stable level of staffing on the regular budget, by restructuring, reassignments and strategic investment of alternative funding sources.

Objective 3 - Evaluate and implement cancer prevention and control strategies

The focus on “cancer research for cancer prevention” runs throughout all the Agency’s research areas, but is most directly evidenced by studies evaluating interventions for prevention and early detection of cancers, and research on their effective implementation. Indeed the Agency has major opportunities to work in close cooperation with national programmes in order to assess the factors which help or hinder the implementation of cancer control measures and to evaluate their impact on cancer burden. Thus research has been extended to encompass a broader commitment to studies at a programmatic level within the context of health service provision.

Research on preventive interventions includes strategies for prevention and early detection of cancers with a high burden in LMICs, from trials of vaccines against hepatitis B virus (HBV) or human papillomavirus (HPV), or on the eradication of Helicobacter pylori (H. pylori), through to studies evaluating simple and affordable screening methods and new technologies for cervical, breast, colorectal and oral cancer.

Implementation research involves the study of operational, cultural and socioeconomic factors affecting the successful implementation and scale-up of interventions for prevention and early detection of cancer in routine health services at national or regional level. The work on prevention has also expanded to consider the factors, both pre- and post-diagnosis which influence prognosis and quality of life. Work with national centres permits patterns of care to be evaluated, providing the evidence-base for implementation of improvements in clinical management of cancer. It is notable that laboratory methods are also providing new avenues for early detection and studies of prognosis, for example with respect to tumour DNA detected in blood.

In addition to original research on cancer prevention the Agency coordinates international expert evaluations of the published scientific evidence on the effectiveness of primary and secondary cancer prevention interventions. These evaluations are primarily published in the IARC Handbooks of Cancer Prevention, in an approach complementary to that of the IARC Monographs. The number of areas able to be evaluated by the Handbooks series will be largely dependent on the success of additional resource mobilization efforts.

Major contributions to Objective 3 are made by EDP, INF, ENV, the Gambia Hepatitis Intervention Study (GHIS) and IMO, with further contributions from CSU and NME.

This area includes three broad categories of projects which aim:

a. to enhance understanding of interventions for cancer prevention and control;

b. to enhance the implementation of cancer prevention and control programmes;

c. to provide expert evaluations of the available evidence-base in order to recommend prevention strategies.

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 9 The 2016–2017 budget saw a significant increase of nearly €2 million assigned to Objective 3 compared to 2014–2015, resulting in an allocation of 10.18% of the overall budget compared to 5.61%. The proposed 2018–2019 budget maintains a similar overall level of allocation but with some important underlying changes in distribution.

The fieldwork for the long-term GHIS project will be completed by the end of 2018. Therefore, given budgetary constraints and competing demands, a decision has been taken to cut the regular budget support to the GHIS project during the biennium, resulting in a reduction of €169 600 to this project’s budget in 2018–2019 compared to 2016–2017. This reduction enables the maintenance of key positions in other areas of the Agency’s Programme under Objective 3. Nevertheless, given the valuable research platform of the GHIS in The Gambia, co-located with the Medical Research Council UK Gambia Unit, extrabudgetary resources will be sought for new research projects in the hope of maintaining the IARC staff and infrastructure in this unique field setting.

The opportunities for research on prevention and implementation continue to grow. In order to support these initiatives and to add value to extrabudgetary resources, the Agency has used UB to support two scientist positions and a new database manager post in EDP over the 2018–2019 biennium, studying the prevention of gastric, cervical and breast cancers.

In order to permit the relaunch of the Handbooks of Cancer Prevention, additional time has been allocated from existing scientific and support staff in IMO, combined with an allocation of a scientist position financed from the UB. The non-staff budget for the Handbooks has also been increased on the regular budget by €95 800, enabled by changes to the GHIS project mentioned above.

The evaluation of cancer prevention initiatives in one region highlights opportunities and the potential added-value in transferring these experiences to other regions of the world. Two examples are the European Code against Cancer (ECAC) and the Implementation of Cancer Screening in the European Union. The ECAC was developed under the leadership of the Agency. There are opportunities to build on and modify this Code and the underlying methodology for other regions of the world, if additional resources can be identified. A modest resource has been assigned in the 2018–2019 proposed budget to facilitate this initiative. Following the studies of the implementation of cancer screening in Europe the Agency has identified a number of quality indicators which could be applied in other geographic regions to track progress on screening programmes. A proposed Cancer Screening in Five Continents project will be the subject of resource mobilization efforts, permitting periodic evaluation of population based cancer screening programmes in different countries using a basic set of process and outcome measures in a harmonized manner.

Objective 4 - Increase the capacity for cancer research

The development of capacity for cancer research is one of the statutory roles of IARC and thus remains a key element of its mission. However, the contributions under this broad objective cover three main and rather distinct components.


The first component is focused on people with the aim of developing knowledge and skills in cancer research with emphasis on countries where capacity remains limited. The education and training programme is restricted to core areas of IARC expertise and is integrated with the scientific activities, meaning much of the training is delivered in the context of collaborative research projects. More structured training is provided through the fellowships and courses programmes hosted at IARC (including the IARC Summer School) and training courses associated with specific projects. The Agency has worked with international partners to create and develop the Biobank and Cohort Building Network in low-income countries, providing training in biobanking and the associated legal and ethical considerations. In order to improve access to learning materials the Agency places increasing effort into producing e-Learning materials and translations into different languages beyond the two official IARC languages.

The second component is focused on methods, notably the development of research capacity and tools for epidemiology and laboratory research, such as new or improved methodologies in biostatistics, bioinformatics, exposure assessment and biomarkers. Increased emphasis on statistical methods and modelling, for example of the burden of cancer linked to certain exposures or the impact of different preventive interventions, permit the benefits of investments to be more easily considered at national or international level. The wider range of methodological developments are closely aligned to ongoing research on causes and prevention of cancer and frequently find application to projects assigned to Objectives 2 and 3 of the Project Tree, often preceded by pilot studies.

The third component under this objective is the provision of infrastructure for research. This comprises support in information technology, laboratory services and platforms (genetics, histology) and biobanking facilities.

The overall coordination of the formal training activities of the Agency is provided by the Education and Training Group (ETR) within the Director’s Office. Training courses associated with specific projects are delivered by those Sections involved, with examples from EDP, CSU, NME, LSB and GEN. Several different Sections are involved in methods development including INF, ENV, NME, MCA, and GEN, while the infrastructure for research is provided mainly through the Laboratory Services and Biobank Group (LSB) and the Section of Support to Research (SSR). In addition, strategic research investment is managed through the Director’s Office (DIR).

The main objectives in this area are therefore:

a. to increase human resources for cancer research;

b. to develop new methodologies for cancer research;

c. to provide the resources and infrastructure to support and enhance research.

Overall, the resources assigned to this area have seen an increase to 25.58% of the proposed budget for 2018–2019, from 23.68% in 2016–2017. This increase partly reflects changes in emphasis for some of the existing research Sections. Most notably the NME Section has been restructured following the arrival of a new Section Head, with the Dietary Exposure Assessment Group (DEX) being abolished and the creation of a new Nutritional Methodology and Biostatistics Group (NMB). Through these changes NME has focused additional resources into methodologies which fall under area (b) mentioned above. In addition, GEN has assigned more staff resources

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 11 to maintaining some of the exceptional epidemiological cohort studies available to IARC (e.g. in Russian Federation and Iran) as well as a new initiative to create a European Cohort Consortium.

In relation to area (a), the Agency faces a reduction in activity, nearly halving the number of available IARC Fellowships (from an average of 18 two-year awards per biennium to just 10) because of changes in eligibility for extrabudgetary funding from the European Commission. In order to maintain an effective programme while pursuing alternative funding, the Agency will henceforth restrict the award of IARC Fellowships to candidates from LMICs and has assigned an additional €80 000 in the 2018–2019 budget to the Fellowship Programme to partially mitigate the above changes and allow the award of one additional Fellowship, bringing the total to 11 two-year Postdoctoral Fellowships funded on the regular budget over the biennium.

Objective 5 - Provide strategic leadership and enhance the impact of the Agency’s contribution to global cancer research

This area comprises the activities relating to the definition and implementation of the scientific strategy and programme, supporting the fulfilment of the Agency’s objectives and its leadership in promoting and shaping cancer prevention and control internationally.

The Director is responsible for defining the vision, setting the strategy, and overseeing the implementation of the Agency’s research programme, being supported in these functions by the Senior Leadership Team (SLT), and at an operational level by the Heads and senior staff in each of the Sections and Groups.

This area also includes the support to the governance structures of IARC, the management of strategic partnerships and of communications, as well as the oversight of compliance with ethical and professional standards in the Agency’s activities and research. Success depends on the development and maintenance of key strategic partnerships with WHO, other UN agencies, regional cancer networks, national cancer organizations, non-governmental organizations, etc.

Dissemination of IARC’s research is a foundation to translating the scientific findings into cancer control measures and also falls under this objective.

Activities in this area are coordinated primarily by the Director’s Office (DIR) and its Communications Group (COM) with contributions from the Section of Support to Research (SSR) and all scientific Sections.

The main objectives in this area are therefore:

a. to define the vision and implement the scientific strategy for the Agency, providing the framework for the fulfilment of its objectives;

b. to oversee the strategic direction of the Agency and the implementation of its programme;

c. to create and maintain key strategic partnerships with national, regional and international organizations;

d. effectively communicate and disseminate the work of the Agency.

The Agency is rightly subject to scrutiny of its policies and procedures, particularly when performing evaluation of carcinogenic agents, preventive interventions, or classification of


tumours, for example. There is need for standard, streamlined approaches to assessing perceived or real conflicts of interest among all the scientists IARC calls upon as experts as well as the potential donors to its work. The new WHO Framework for Engagement with Non-State Actors and the WHO Ethics and Compliance Office provide important points of reference for the Agency in this context. Efficient and transparent ethical evaluation of all IARC projects remains an essential foundation to all research conducted by Agency scientists. In order to be able to coordinate these areas in an efficient and effective manner and to be able to liaise with colleagues at WHO, the Agency has decided to add one junior professional post to the Director’s Office in the role of Ethics and Compliance Officer. This investment explains the overall increase in total posts by 0.4 in the 2018–2019 budget compared to the previous biennium.

IARC can add value to its research outputs by increasing the dissemination of its findings. During the 2014–2015 biennium the Agency allocated resources for the first time to a Press Officer. In the 2018–2019 biennium the need for an additional post, focused on social media and other multimedia communication formats, has been identified as a priority. In order to maintain the current staffing quota on the regular budget and to avoid reducing scientific staff, this general service staff position is to be financed from the Programme Support Cost account rather than the regular budget.

In addition to the above-mentioned areas, which concern predominantly internal functions, the Agency is also able to shape the international cancer research agenda externally. This latter role is achieved in a number of different ways. First, senior IARC scientists are frequently invited to participate in national and international fora, committees, working and advisory groups to advise on cancer research and cancer control agendas. These contributions are not easily attributed a given amount of person-time and are therefore encompassed within the resource allocation to Objectives 1 to 4 inclusive. It is intended, however, to present these contributions as a part of the Medium-Term Strategy Evaluation Framework. Second, there are specific initiatives taken at an Agency level to shape the international agenda. Specific examples include the Cancer Prevention Europe (CPE) initiative, cooperation with WHO to promote cancer control among Member States and the contribution to the United Nations Inter-Agency Task Force (IATF) on NCDs. In the case of CPE, the Agency has assembled a consortium of a number of leading European cancer research centres to define the scope of cancer prevention, identify the major contributors and advocate for the topic at a European level. This initiative may serve as a model for other regions. In relation to WHO Member States, the Agency is working, for example, with colleagues at WHO towards a cancer resolution at the World Health Assembly 2017. IARC is also an active member of two of the three multi-agency joint projects emerging from the IATF, in close collaboration with WHO and other UN partners.

In terms of budget allocation, Objective 5 represents almost the same proportion of the proposed budget 2018–2019 as in the previous biennium (10.65% compared to 10.27%). The increase is related to the additional P2 position of Ethics and Compliance Officer in the Director’s Office.

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 13 Objective 6 - Enable and support the efficient conduct and coordination of research

This objective groups the broad range of activities of IARC’s general management and administrative support structures, which enable the efficient implementation of the scientific programmes, operational effectiveness and optimal management of the Agency’s human, material and financial resources. It comprises activities such as finance, human resources, information technology, and general administrative support, including premises security. Sound financial management ensures that expenditures are properly authorized, processed and recorded, that assets are safeguarded and liabilities correctly quantified, and that financial reporting is accurate and timely.

Activities in this area are undertaken by the Section of Support to Research (SSR) in close collaboration with all the scientific Sections and Groups.

This area includes projects whose primary objectives are:

a. to ensure the Agency is directed and managed according to highest sector standards;

b. invest strategically towards increasing IARC’s capacity.

The regular budget allocated to this area will be further reduced in biennium 2018–2019. This is the result of a sustained effort by SSR to improve the efficiency of services by streamlining processes, renegotiating major external contracts, and increasing the effectiveness of general management and administrative services staff, while further reducing administrative costs by introducing additional cost-efficiency measures. In global terms this resulted in a decrease of the administrative budget as a fraction of the total regular budget to 19.69% in 2018–2019 from 20.17% in 2016–2017.

A novel Business Intelligence tool, aligned with evolving business needs and trends, will provide senior management with transparent, up to date, and accurate information in support of the decision-making process. IARC has reviewed its investments in Enterprise Resource Planning (ERP) solutions over the past 8 years and validated its plan for future IT investments to further automate essential administrative processes.

IARC volunteered to take part in the Project Management Institute (PMI) Project Management Excellence initiative led by WHO and supported by the Bill and Melinda Gates Foundation. Against a set of standard operational efficiency and effectiveness indicators, this initiative resulted in a favourable self-assessment for IARC in 2016, which will be used as a benchmark for further improvements in future biennia.

Consistent with the goals of improved compliance and achievement of general management and administrative excellence, IARC has set out to close all pending audit recommendations from previous years. This is a major achievement, reflecting the full commitment of IARC senior management.

The Nouveau Centre building project is on track with the construction and fitting works scheduled from 2018 to 2021.


3. PROPOSED BUDGET 2018–2019

The proposed budget 2018–2019 is the second biennial budget within the MTS 2016–2020. It is developed in euros in accordance with Article III.3.1 of the IARC Financial Regulations. The presentation of the proposed budget follows the structure set out in the IARC Project Tree according to the six main Level 2 objectives with further details at the Level 3 objectives in some tables.

3.1 Explanation of the proposed regular budget

3.1.1 Overall regular budget and distribution

The regular budget proposed for 2018–2019 biennium is €45 073 300. The distribution of the proposed budget reflects the prioritization of resources across the six main objectives of the Project Tree as described in section 2 of this document. The table below compares the distribution of the proposed regular budget with the previous approved biennial budget.

Level 2 Objectives 2016–2017

(in euros) % 2018–2019

(in euros) % 1. Describe the occurrence of cancer 3 170 478 7.30 3 507 393 7.78

2. Understand the causes of cancer 12 325 676 28.39 11 871 734 26.34

3. Evaluate and implement cancer prevention and control strategies

4 420 264 10.18 4 487 103 9.96

4. Increase the capacity for cancer research 10 281 347 23.68 11 531 303 25.58

5. Provide strategic leadership and enhance the impact of the Agency’s contribution to global cancer research

4 458 253 10.27 4 800 745 10.65

6. Enable and support the efficient conduct and coordination of research

8 757 581 20.17 8 875 022 19.69

Total 43 413 599 100.00 45 073 300 100.00

Further information of the proposed budget can be found in Summary Tables A, B, C, D, and E. 3.1.2 Staff and non-staff budget distribution

The non-staff budget for 2018–2019 is kept at the same level as in the 2016–2017 budget and the majority is designated for staff costs as shown in the below table. More details of the distribution at objective level are available in Summary Table C.

Budget category 2016–2017

(in euros) % 2018–2019

(in euros) %

Staff budget 32 845 309 75.66 34 484 790 76.51

Non-staff budget 10 568 290 24.34 10 588 510 23.49

Total 43 413 599 100.00 45 073 300 100.00

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 15 Overall, the total number of posts to be funded from the regular budget increases by 0.40 as compared to 2017. The staff budget reflects statutory staff cost increase, net changes in distribution and level of posts resulting from various reorganizations within the Agency during 2016–2017 and foreseen for 2018–2019, including investments in the bioinformatics area.

Staff category 2016 2017 2018 2019

Professional (P) 72.50 73.10 74.00 74.00

General Service (GS) 85.78 85.70 85.20 85.20

Total number of posts 158.28 158.80 159.20 159.20

% Distribution of P:GS 46:54 46:54 46:54 46:54

Summary Table D provides further details on post distribution.

3.1.3 Cost increase

The proposed budget is 3.82% higher than the 2016–2017 approved budget, 2.71% representing a portion of the statutory staff cost increases and 1.11% due to programmatic changes, as summarized below.

For more details, please refer to Summary Tables F and G.

Cost component

Due to programmatic

changes (in euros)

Due to statutory cost

changes (in euros)

Total changes (in euros)

Staff cost increase 462 330 1 177 151 1 639 481

Non-staff cost increase 20 220 0 20 220

Total cost increase 482 550 1 177 151 1 659 701

Total % increase 1.11% 2.71% 3.82%

While non-staff cost remains stable, the staff cost increases foreseen over the next biennium is €1.64 million, €1.18 million due to statutory cost increase and €0.46 million due to programmatic changes.

• Statutory cost increase: The statutory staff cost increase is largely the result of annual step increases for all staff categories and cost adjustments for General Service staff. No cost adjustment for international staff is anticipated and therefore no provision is included in the budget.

• Programmatic changes: The staff cost increase due to programmatic changes reflects the net effect of internal reorganizations resulting from the abolishment and creation of new posts, and revision in grade of existing posts.

To reduce staff cost pressure, the Agency applies a lower TQ rate at 9% instead of 10% to the standard staff cost. The TQ fund was established for financing short term employee benefits and


since 2010, the TQ account has been funded by a budgetary provision set at the rate of 10% of professional staff salary and post adjustment, collected through the payroll.

Implementation of the new compensation package for international staff as recommended by the International Civil Servants Commission (ICSC) within WHO and IARC is planned with effective date from 1 January 2017 and accordingly the new conditions of services of staff in the Professional and higher categories are reflected in this budget. 3.2 Financing of the regular budget

Funds from the GCSF account, totalling €2.00 million, were approved to partially finance IARC’s regular budget since 2012 (i.e. €1.00 million for 2012–2013 budget, €0.50 million for 2014–2015 budget, and €0.50 million for 2016–2017 budget). To phase out this reliance on the GCSF, the 2018–2019 regular budget is proposed to be solely funded from assessed contributions from Participating States as presented in the table below. This includes the contribution from Morocco joining IARC in 2015 and starting to pay its full assessed contributions towards the 2018–2019 Programme Budget, in accordance with Governing Council Resolution GC/57/R1.

Funding Source 2016–2017

(in euros) 2018–2019

(in euros) % Change

Assessed contributions (excl. Morocco) 42 913 599 43 811 248 2.09%

Assessed contributions from Morocco 0 1 262 052 2.94%

Total assessed contributions 42 913 599 45 073 300 5.03%

GCSF 500 000 0

Total regular budget 43 413 599 45 073 300 3.82%

The proposed budget represents an overall increase of €1.66 million or 3.82% from the previous biennium to enable the Agency to cover programmatic changes and increased statutory staff costs. This is largely made possible by Morocco’s full contributions of approximately €1.26 million, together with an increase of just under €0.90 million of the assessed contributions from the remaining 24 Participating States, in large part to cover the proposed absence of GCSF financing. Assessments on Participating States:

The assessments on Participating States are based on the method approved by the Governing Council under Resolution GC/15/R9, which references group classification of countries to the WHO scale of assessment that is in turn based on the United Nations scale of assessment.

In December 2015, the United Nations General Assembly adopted a new scale of assessment for the three-year period 2016–2018 (United Nations General Assembly Resolution 70/245), leading to the revision of the WHO scale of assessments which was approved by the World Health Assembly in May 2016 (Resolution WHA69.14). This WHO revised scale of assessment is the basis for group classification and assessment on IARC Participating States in the proposed 2018–2019 budget.

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 17 Summary Tables H and I provide the details of year-on-year financing and assessments of contribution for each Participating State. The impact of the proposed budget on each individual Participating State as compared to the approved 2016–2017 budget varies between 0.83% and 5.89%, with exceptions on three Participating States, as summarized below.

% Change Amount change*

(in euros) Participating States (excluding Morocco)

0.83% 10 405 Group 5: Ireland, Qatar

2.18% 24 681 Group 4: Austria, Belgium, Denmark, India, Netherlands, Norway, Sweden, Switzerland, Turkey

3.16% 54 866 Group 3: Australia, Brazil, Canada, Russian Federation, Spain

4.47% 99 325 Group 2: France, Germany, United Kingdom

5.89% 188 248 Group 1: Japan, United States of America

-15.56% (232 502) Finland – changed from Group 4 to 5

-19.38% (430 948) Italy – changed from Group 2 to 3

19.92% 297 773 Republic of Korea – changed from Group 4 to 3

*Amount increase/(decrease) is for the biennium budget. The revision of the WHO scale of assessment as mentioned above results in Finland, Italy, and Republic of Korea changing grouping according to IARC’s assessment method. For reference to group classification and comparison with three previous biennium budgets, please refer to Information Table D. To this effect, Finland and Italy will be paying less as they will move from Group 4 to 5 and from Group 2 to 3, respectively. Republic of Korea will move back to Group 3 where it was in the 2012–2013 biennium and prior budget periods, resulting in an increase in its assessment. The reduction of assessments to Finland and Italy have to be absorbed by all other Participating States, including Republic of Korea, accordingly.

Should the WHO scale of assessment have remained unchanged, the impact of the proposed budget increase and an absence of GCSF financing would have been distributed across all Participating States more consistently between 0.83% and 3.39%. Information Table E comparing the assessments on Participating States based on the current and revised scales is provided in the Annex for illustration purpose. 3.3 Extrabudgetary resources

Secured extrabudgetary resources:

IARC programme and budget planning follows the integrated budget approach by considering all funding sources from both regular and extrabudgetary resources for implementing the proposed programme. Extrabudgetary resources include the secured voluntary designated contributions at the time of budget preparation (September 2016) and resources from the PSC account and the GCSF account.

The estimated extrabudgetary resources are expected to increase significantly in the proposed budget 2018–2019, as shown below. More details are available in Summary Tables B and E.


Level 2 Objectives 2016–2017

(in euros) % 2018–2019

(in euros) % 1. Describe the occurrence of cancer 1 320 347 16.03 1 548 154 9.45

2. Understand the causes of cancer 1 293 487 15.70 5 878 621 35.86

3. Evaluate and implement cancer prevention and control strategies

1 339 895 16.27 3 823 810 23.33

4. Increase the capacity for cancer research 1 782 432 21.64 1 503 440 9.17

5. Provide strategic leadership and enhance the impact of the Agency’s contribution to global cancer research

327 789 3.98 998 669 6.09

6. Enable and support the efficient conduct and coordination of research

2 172 736 26.38 2 638 350 16.10

Total 8 236 686 100.00 16 391 044 100.00

This increase in availability of extrabudgetary resources reflects the on-going success of the Agency’s scientists in obtaining competitive research funding and growing direct contributions, notably the multi-year grants supporting Objectives 2, 3 and 4, while several investments from PSC and GCSF accounts are distributed across other objectives.

Funds in the PSC account are collected from designated voluntary contributions and are utilized mainly in Objective 6. The Agency is increasing its investment of PSC funds and in biennium 2018–2019 plans to continue to strengthen its capacity in the areas of social media and communication (Objective 5) by adding a new LY5/Social Media post in the Communications Office. The PSC fund would also be used to support the Nouveau Centre project, preparing the move to the new building (Objective 6).

Funds from the GCSF account include 75% of the revenue from publications, which are returned to the Publications programme, supporting inter alia the production of the WHO Classification of Tumours Series (Objectives 1 and 5). They also include the UB allocated to supplement the limited regular budget to build up the bioinformatics area (Objectives 2 and 4).

Resource gaps:

Notwithstanding the increased success thus far in mobilizing voluntary contributions as well as raising funds through PSC and GCSF, several high value projects of the Agency still have large funding shortfalls, hindering their potential and risking their continuity. Amongst those, seven projects listed below are of highest priority for resource mobilization with a total target of €13.72 million for 2018–2019. Additional information in reference to these projects including project summary and expected deliverables are provided in Information Table G.

1. Global Initiative for Cancer Registry Development (GICR) (Objective 1). The GICR aims to contribute to the development of in-country capacity for cancer surveillance through structured support to high-quality population-based cancer registries. Coordinated by IARC, six IARC Regional Hubs serve as a first point of contact to provide technical training, consultancies through site visits, mentorship and analysis to produce scientific and policy reports. To implement these activities, a budget of €5.98 million is required for the biennium,

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 19

of which €1.64 million is being sought to support core infrastructure costs and operations of the six IARC Regional Hubs.

2. IARC Monographs Programme (Objective 2). In view of the worldwide impact of the Monographs and the capacity within the current team to publish the results soon after the assessments of agents and exposures that present carcinogenic hazards to humans, the programme urgently requires additional staff with expertise in quantitative exposure assessment and in scientific editing to help to shorten the time interval from the conclusion of an evaluation to the publication of the final Monograph. Additional funding of €0.42 million is required for the biennium.

3. Multicentric study of cervical cancer screening and triage with human papillomavirus testing (ESTAMPA) (Objective 3). ESTAMPA is an international effort in Latin America to implement organized HPV-based cervical screening and reduce cervical cancer mortality among women in the region. The budget of the study for 2016–2020 amounts to €15 million, including €2 million required for the 2018–2019 biennium. In-kind contributions are expected from local governments and universities participating in the study. The additional voluntary contributions will accelerate the evaluation of new biomarkers and approaches for cervical cancer control and consolidate the wide network of investigators in the region.

4. Cancer Screening in Five Continents (CanScreen5) (Objective 3). This emerging project is expected to result in country improvements in screening programme management and quality assurance, strengthening health information systems, and ultimately in supporting the collection of screening data and promoting their use, informing policy development and research in cancer prevention and early detection. This new project remains mostly unfunded. The five year project budget is estimated at €3.00 million with the estimated amount of €1.2 million required for the 2018–2019 biennium, i.e., first phase.

5. IARC Handbooks of Cancer Prevention (HCP) (Objective 3). Since their re-launch in 2014, Handbooks have been scheduled every 18 months on average, with very limited resources, and support from the staff of the Monographs Programme. The aim is to secure long-term funding dedicated to the Handbooks to build the sustainability of the programme to be able to publish one Handbook per year. The total cost of one Handbook is €0.52 million, hence €1.04 million funding would be required for the 2018–2019 biennium.

6. IARC Fellowship Programme (Objective 4). The programme has contributed to the development of human resources for cancer research worldwide. The Agency remains particularly committed to promoting the development of expertise in cancer research in LMICs by training researchers from these countries. External funding for this programme was secured through two consecutive EC MSCA FP7-COFUND grants, complemented with bilateral agreements with Cancer Council Australia and the Irish Cancer Society, which allowed the expansion of the Fellowships since 2010. Additional funding is being sought to ensure its sustainability as the Agency was informed in 2015 that it is no longer considered eligible for the EU co-funding. To be able to maintain the same number of fellowships awarded per year, a shortfall of €0.56 million needs to be met over the biennium through other funding sources.


7. IARC “Nouveau Centre” Plus (Objective 6). The total budget of €49.26 million has been secured for the Nouveau Centre core project to cover building costs and partially cover infrastructure and equipment costs. Additional funding of €7.78 million is required to cover additional costs not included in the core project budget, such as design and installation of offices, meeting rooms and public facilities; renewal of IARC’s scientific equipment; and physical move to the new premises. €5.04 million of this additional funding requirement remains unfunded and will need to be mobilized over the next five years, with the target of €2.52 million for 2018–2019.

Overall budget inclusive of extrabudgetary resources:

Should the resource gaps of the seven priority projects be filled, the budget for implementation of activities in the 2018–2019 biennium, combining with the proposed regular budget and extrabudgetary resources already secured, would be €75.18 million. Figure 4 provides an overview of resource distribution by six priority objectives, inclusive of the project resource gaps. It should be noted that this Figure does not include additional extrabudgetary resources required for other areas of MTS activity that would normally be anticipated to be obtained from competitive funding sources during the biennium.

Figure 4 – Resource distribution inclusive of gaps in seven priority projects

The proposed regular budget for 2018–2019 amounting to €45.07 million is around 60% of all the above resources combined, representing the foundation needed to implement the activities necessary to deliver the MTS.

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 21 4. BUDGET TABLES

The proposed 2018–2019 budget is presented in the following nine summary tables, of which six tables include the 2016–2017 approved budget for comparison purposes.

• Table A - Proposed regular budget for the biennium 2018–2019: Provides the overall proposed budget including the breakdown of budget at the level 2 objectives of the IARC Project Tree for the biennium.

• Table B - Summary of biennial resources by level 2/3 objectives and sources of fund: Includes financial resources overview with breakdown of budget at the level 2 and level 3 objectives of the IARC Project Tree inclusive of the proposed regular budget allocations and projected extrabudgetary resources (i.e. voluntary contributions, PSC account, and GCSF). The 2016–2017 figures are also provided for comparison.

• Table C - Summary of regular budget by level 2/3 objectives and year: Presents further details of the proposed regular budget allocations by year, broken down by staff and non-staff budget.

• Table D - Summary of regular budget funded staff by level 2/3 objectives and staff category: Summarizes the staff in person-years funded by regular budget, allotted to each objective at the level 2 and level 3 objectives of the IARC Project Tree in comparison with the approved figures of 2016–2017. Number of staff is grouped according to the staff categories.

• Table E - Analysis of staffing and resources by level 2/3 objectives: Provides details of the proposed budget and staffing for 2018–2019 at the level 2 and level 3 objectives of the IARC Project Tree.

• Table F - Summary of budget changes from previous biennial budget: Illustrates overall changes to the budget level for 2018–2019 from the approved budget 2016–2017.

• Table G - Summary of regular budget by component and cause of increase/decrease: Presents the proposed budget by component of expenditure in comparison with the approved budget 2016–2017. The increases or decreases are classified based on two main criteria, i.e. programme requirement and cost changes.

• Table H - Summary of regular budget and proposed financing: Provides a summary of the proposed regular budget and proposed funding sources by year, in comparison with those approved for the 2016–2017 budget.

• Table I - Summary of proposed financing from assessments on Participating States and Governing Council Special Fund: Provides the details of assessments on Participating States and other resources required to fund the proposed budget, including comparison with those approved for the 2016–2017 budget.


LEVE

L 2

OBJE

CTIV

ES20

18-2

019

BUDG

ET%

1.

Des

crib

e th

e oc

curr

ence

of c

ance

r3,

507,

393

7.78

2.

Und

erst

and

the

caus

es o

f can

cer

11,8

71,7

3426

.34

3.

Eva

luat

e an

d im

plem

ent c

ance

r pre

vent

ion

and

cont

rol s

trate

gies

4,48

7,10

39.

96

4.

Incr

ease

the

capa

city

for c

ance

r res

earc

h11

,531

,303

25.5

8

5.

Pro

vide

stra

tegi

c le

ader

ship

and

enh

ance

the

impa

ct o

f the

Age

ncy’s

con

tribu

tion

to g

loba

l can

cer r

esea

rch

4,80

0,74

510

.65

6.

Ena

ble

and

supp

ort t

he e

fficie

nt c

ondu

ct a

nd c

oord

inat

ion

of re

sear

ch8,

875,

022

19.6

9

TOTA

L BU

DGET

45,0

73,3

0010

0.00

Sum

mar

y Ta

ble

APR

OPOS

ED R

EGUL

AR

BUDG

ET F

OR T

HE B

IENN

IUM

201

8-20

19(e

xpre

ssed

in e

uros

)


Le

vel 2

Leve

l 2 O

bjec

tives

Leve

l 3Le

vel 3

Obj

ectiv

es20

16-2

017

2018

-201

920

16-2

017

2018

-201

9Bu

dget

Am

ount

%Bu

dget

Am

ount

%Bu

dget

Am

ount

Budg

et A

mou

nt

1De

scrib

e th

e oc

curr

ence

of c

ance

r1.

1Im

prov

e an

d ex

pand

repo

rting

of d

escr

iptive

canc

er st

atist

ics1,

958,

877

2,07

1,81

50

133,

103

1.2

Supp

ort i

mpr

oved

cove

rage

and

qua

lity o

f can

cer r

egist

ratio

n, p

artic

ularly

in lo

w an

d m

iddle-

incom

e co

untri

es (L

MIC)

848,

717

867,

061

142,

000

234,

706

1.3

Impr

ove

tum

our c

lassif

icatio

n to

info

rm ca

ncer

regis

tratio

n, re

sear

ch a

nd tr

eatm

ent

362,

884

568,

517

1,17

8,34

71,

180,

345

3,17

0,47

87.

303,

507,

393

7.78

1,32

0,34

71,

548,

154

2Un

ders

tand

the

caus

es o

f can

cer

2.1

Iden

tify t

he ri

sk fa

ctors

for h

uman

canc

er th

roug

h th

e co

nduc

t of e

pidem

iolog

ical s

tudie

s7,

056,

412

7,16

7,59

51,

131,

487

3,67

3,38

62.

2Elu

cidat

e m

echa

nism

s of c

arcin

ogen

esis

thro

ugh

the

cond

uct o

f lab

orat

ory s

tudie

s3,

575,

915

2,82

5,40

216

2,00

062

3,63

62.

3Pr

ovide

exp

ert e

valua

tions

of t

he a

vaila

ble e

viden

ce-b

ase

to id

entif

y hum

an ca

rcino

gens

1,69

3,34

91,

878,

737

01,

581,

599

12,3

25,6

7628

.39

11,8

71,7

3426

.34

1,29

3,48

75,

878,

621

3Ev

alua

te a

nd im

plem

ent c

ance

r pre

vent

ion

and

cont

rol s

trat

egie

s3.

1En

hanc

e un

ders

tand

ing o

f int

erve

ntion

s for

canc

er p

reve

ntion

and

cont

rol

2,63

9,00

02,

675,

647

398,

838

1,00

0,26

13.

2En

hanc

e th

e im

plem

enta

tion

of ca

ncer

pre

vent

ion a

nd co

ntro

l pro

gram

mes

1,34

3,83

31,

200,

231

941,

057

2,67

9,89

93.

3Pr

ovide

exp

ert e

valua

tions

of t

he a

vaila

ble e

viden

ce-b

ase

in or

der t

o re

com

men

d pr

even

tion

strat

egies

437,

431

611,

225

014

3,65

04,

420,

264

10.1

84,

487,

103

9.96

1,33

9,89

53,

823,

810

4In

crea

se th

e ca

pacit

y fo

r can

cer r

esea

rch

4.1

Incr

ease

hum

an re

sour

ces f

or ca

ncer

rese

arch

1,63

2,19

31,

754,

571

827,

042

684,

401

4.2

Deve

lop n

ew m

etho

dolog

ies fo

r can

cer r

esea

rch

2,88

0,76

93,

686,

713

195,

438

288,

701

4.3

Prov

ide th

e re

sour

ces a

nd in

frastr

uctu

re to

supp

ort a

nd e

nhan

ce re

sear

ch5,

768,

385

6,09

0,01

968

1,41

453

0,33

810

,281

,347

23.6

811

,531

,303

25.5

81,

703,

894

1,50

3,44

0

5Pr

ovid

e st

rate

gic

lead

ersh

ip a

nd e

nhan

ce th

e im

pact

of t

he A

genc

y’s

cont

ribut

ion

to g

loba

l can

cer r

esea

rch

5.1

Defin

e th

e vis

ion a

nd im

plem

ent t

he sc

ientif

ic str

ateg

y of t

he A

genc

y, pr

ovidi

ng th

e fra

mew

ork f

or th

e fu

lfilm

ent o

f its

obje

ctive

s1,

284,

291

1,35

9,08

00

05.

2Ov

erse

e th

e str

ateg

ic dir

ectio

n of

the

Agen

cy a

nd th

e im

plem

enta

tion

of it

s pro

gram

me

392,

191

398,

701

00

5.3

Crea

te a

nd m

ainta

in ke

y stra

tegic

par

tner

ships

with

nat

ional,

regio

nal a

nd in

tern

ation

al or

ganiz

ation

s42

4,88

961

7,67

50

05.

4Ef

fecti

vely

com

mun

icate

and

diss

emina

te th

e wo

rk o

f the

Age

ncy

2,35

6,88

22,

425,

289

327,

789

998,

669

4,45

8,25

310

.27

4,80

0,74

510

.65

327,

789

998,

669

6En

able

and

sup

port

the

effic

ient

con

duct

and

coo

rdin

atio

n of

rese

arch

6.1

Ensu

re th

e Ag

ency

is d

irecte

d an

d m

anag

ed a

ccor

ding

to h

ighes

t sec

tor s

tand

ards

8,24

8,42

18,

396,

099

2,16

1,07

42,

489,

974

6.2

Inve

st str

ateg

ically

towa

rds i

ncre

asing

IARC

’s ca

pacit

y 50

9,16

047

8,92

390

,200

148,

376

8,75

7,58

120

.17

8,87

5,02

219

.69

2,25

1,27

42,

638,

350

TOTA

L43

,413

,599

100.

0045

,073

,300

100.

008,

236,

686

16,3

91,0

44

Note

s:i.

Extr

a-bu

dget

ary r

esou

rces

inclu

de V

olunt

ary C

ontri

butio

ns se

cure

d at

the

time

of b

udge

t sub

miss

ion, f

undin

g fro

m th

e Pr

ogra

mm

e Su

ppor

t Cos

t Acc

ount

and

the

Gove

rning

Cou

ncil S

pecia

l Fun

d.

Sum

mar

y Ta

ble

BSU

MM

ARY

OF B

IENN

IAL

RESO

URCE

S BY

LEV

EL 2

/3 O

BJEC

TIVE

S AN

D SO

URCE

S OF

FUND

(exp

ress

ed in

eur

os)

Ex

tra-B

udge

tary

Res

ourc

es(s

ee n

ote

i)Re

gular

Bud

get


Leve

l 2Le

vel 2

Obj

ectiv

es20

1820

1920

18-2

019

Leve

l 3Le

vel 3

Obj

ectiv

esSt

aff

Non-

Staf

fTo

tal

Staf

fNo

n-St

aff

Tota

lSt

aff

Non-

Staf

fTo

tal

Budg

etBu

dget

Budg

etBu

dget

Budg

etBu

dget

1De

scrib

e th

e oc

curr

ence

of c

ance

r1.

1Im

prov

e an

d ex

pand

repo

rting

of d

escr

iptive

canc

er st

atist

ics93

3,57

190

,000

1,02

3,57

195

8,24

490

,000

1,04

8,24

41,

891,

815

180,

000

2,07

1,81

51.

2Su

ppor

t im

prov

ed co

vera

ge a

nd q

uality

of c

ance

r reg

istra

tion,

par

ticula

rly in

low

and

midd

le-inc

ome

coun

tries

(LMI

C)33

3,51

595

,000

428,

515

343,

546

95,0

0043

8,54

667

7,06

119

0,00

086

7,06

11.

3Im

prov

e tu

mou

r clas

sifica

tion

to in

form

canc

er re

gistra

tion,

rese

arch

and

trea

tmen

t22

9,02

053

,000

282,

020

233,

497

53,0

0028

6,49

746

2,51

710

6,00

056

8,51

71,

496,

106

238,

000

1,73

4,10

61,

535,

287

238,

000

1,77

3,28

73,

031,

393

476,

000

3,50

7,39

3

2Un

ders

tand

the

caus

es o

f can

cer

2.1

Iden

tify t

he ri

sk fa

ctors

for h

uman

canc

er th

roug

h th

e co

nduc

t of e

pidem

iolog

ical s

tudie

s3,

079,

733

438,

600

3,51

8,33

33,

215,

062

434,

200

3,64

9,26

26,

294,

795

872,

800

7,16

7,59

52.

2Elu

cidat

e m

echa

nism

s of c

arcin

ogen

esis

thro

ugh

the

cond

uct o

f lab

orat

ory s

tudie

s1,

187,

019

209,

700

1,39

6,71

91,

218,

983

209,

700

1,42

8,68

32,

406,

002

419,

400

2,82

5,40

22.

3Pr

ovide

exp

ert e

valua

tions

of t

he a

vaila

ble e

viden

ce-b

ase

to id

entif

y hum

an ca

rcino

gens

790,

527

140,

000

930,

527

808,

210

140,

000

948,

210

1,59

8,73

728

0,00

01,

878,

737

5,05

7,27

978

8,30

05,

845,

579

5,24

2,25

578

3,90

06,

026,

155

10,2

99,5

341,

572,

200

11,8

71,7

34

3Ev

alua

te a

nd im

plem

ent c

ance

r pre

vent

ion

and

cont

rol s

trat

egie

s3.

1En

hanc

e un

ders

tand

ing o

f int

erve

ntion

s for

canc

er p

reve

ntion

and

cont

rol

1,16

1,41

426

9,50

01,

430,

914

1,05

9,23

318

5,50

01,

244,

733

2,22

0,64

745

5,00

02,

675,

647

3.2

Enha

nce

the

imple

men

tatio

n of

canc

er p

reve

ntion

and

cont

rol p

rogr

amm

es53

3,08

561

,500

594,

585

544,

146

61,5

0060

5,64

61,

077,

231

123,

000

1,20

0,23

13.

3Pr

ovide

exp

ert e

valua

tions

of t

he a

vaila

ble e

viden

ce-b

ase

in or

der t

o re

com

men

d pr

even

tion

strat

egies

235,

269

67,5

0030

2,76

924

0,95

667

,500

308,

456

476,

225

135,

000

611,

225

1,92

9,76

839

8,50

02,

328,

268

1,84

4,33

531

4,50

02,

158,

835

3,77

4,10

371

3,00

04,

487,

103

4In

crea

se th

e ca

pacit

y fo

r can

cer r

esea

rch

4.1

Incr

ease

hum

an re

sour

ces f

or ca

ncer

rese

arch

356,

286

515,

000

871,

286

368,

285

515,

000

883,

285

724,

571

1,03

0,00

01,

754,

571

4.2

Deve

lop n

ew m

etho

dolog

ies fo

r can

cer r

esea

rch

1,59

6,49

520

1,90

01,

798,

395

1,69

2,01

819

6,30

01,

888,

318

3,28

8,51

339

8,20

03,

686,

713

4.3

Prov

ide th

e re

sour

ces a

nd in

frastr

uctu

re to

supp

ort a

nd e

nhan

ce re

sear

ch1,

534,

489

1,47

3,55

03,

008,

039

1,58

2,93

61,

499,

044

3,08

1,98

03,

117,

425

2,97

2,59

46,

090,

019

3,48

7,27

02,

190,

450

5,67

7,72

03,

643,

239

2,21

0,34

45,

853,

583

7,13

0,50

94,

400,

794

11,5

31,3

03

5Pr

ovid

e st

rate

gic

lead

ersh

ip a

nd e

nhan

ce th

e im

pact

of t

he A

genc

y’s

cont

ribut

ion

to g

loba

l can

cer r

esea

rch

5.1

Defin

e th

e vis

ion a

nd im

plem

ent t

he sc

ientif

ic str

ateg

y of t

he A

genc

y, pr

ovidi

ng th

e fra

mew

ork f

or th

e fu

lfilm

ent o

f its

obje

ctive

s40

2,06

327

5,00

067

7,06

340

7,01

727

5,00

068

2,01

780

9,08

055

0,00

01,

359,

080

5.2

Over

see

the

strat

egic

direc

tion

of th

e Ag

ency

and

the

imple

men

tatio

n of

its p

rogr

amm

e87

,994

109,

500

197,

494

91,7

0710

9,50

020

1,20

717

9,70

121

9,00

039

8,70

15.

3Cr

eate

and

main

tain

key s

trate

gic p

artn

ersh

ips w

ith n

ation

al, re

giona

l and

inte

rnat

ional

orga

nizat

ions

231,

759

75,0

0030

6,75

923

5,91

675

,000

310,

916

467,

675

150,

000

617,

675

5.4

Effe

ctive

ly co

mm

unica

te a

nd d

issem

inate

the

work

of t

he A

genc

y93

1,07

127

6,06

01,

207,

131

952,

218

265,

940

1,21

8,15

81,

883,

289

542,

000

2,42

5,28

91,

652,

887

735,

560

2,38

8,44

71,

686,

858

725,

440

2,41

2,29

83,

339,

745

1,46

1,00

04,

800,

745

6En

able

and

sup

port

the

effic

ient

con

duct

and

coo

rdin

atio

n of

rese

arch

6.1

Ensu

re th

e Ag

ency

is d

irecte

d an

d m

anag

ed a

ccor

ding

to h

ighes

t sec

tor s

tand

ards

3,25

2,66

788

6,00

04,

138,

667

3,35

2,91

690

4,51

64,

257,

432

6,60

5,58

31,

790,

516

8,39

6,09

96.

2In

vest

strat

egica

lly to

ward

s inc

reas

ing IA

RC’s

capa

city

149,

971

87,5

0023

7,47

115

3,95

287

,500

241,

452

303,

923

175,

000

478,

923

3,40

2,63

897

3,50

04,

376,

138

3,50

6,86

899

2,01

64,

498,

884

6,90

9,50

61,

965,

516

8,87

5,02

2

TOTA

L17

,025

,948

5,32

4,31

022

,350

,258

17,4

58,8

425,

264,

200

22,7

23,0

4234

,484

,790

10,5

88,5

1045

,073

,300

Sum

mar

y Ta

ble

CSU

MM

ARY

OF R

EGUL

AR B

UDGE

T BY

LEV

EL 2

/3 O

BJEC

TIVE

S AN

D YE

AR(e

xpre

ssed

in e

uros

)


Leve

l 2Le

vel 2

Obj

ectiv

es

Leve

l 3Le

vel 3

Obje

ctive

sPr

ofess

ional

Gene

ral

Total

Profe

ssion

alGe

nera

l To

talPr

ofess

ional

Gene

ral

Total

Profe

ssion

alGe

nera

l To

talan

d abo

veSe

rvice

Staff

and a

bove

Servi

ceSt

affan

d abo

veSe

rvice

Staff

and a

bove

Servi

ceSt

aff

1De

scrib

e th

e oc

curr

ence

of c

ance

r1.1

Impr

ove a

nd ex

pand

repo

rting

of de

scrip

tive c

ance

r stat

istics

3.90

4.70

8.60

3.90

4.70

8.60

3.90

4.70

8.60

3.90

4.70

8.60

1.2Su

ppor

t impr

oved

cove

rage

and q

uality

of ca

ncer

regis

tratio

n, pa

rticu

larly

in low

and m

iddle-

incom

e cou

ntries

(LMI

C)1.1

02.3

03.4

01.1

02.3

03.4

01.1

02.3

03.4

01.1

02.3

03.4

01.3

Impr

ove t

umou

r clas

sifica

tion t

o info

rm ca

ncer

regis

tratio

n, re

sear

ch an

d tre

atmen

t0.4

00.4

00.8

01.0

00.4

01.4

01.0

00.6

01.6

01.0

00.6

01.6

05.4

07.4

012

.806.0

07.4

013

.406.0

07.6

013

.606.0

07.6

013

.60

2Un

ders

tand

the

caus

es o

f can

cer

2.1Ide

ntify

the ri

sk fa

ctors

for hu

man c

ance

r thr

ough

the c

ondu

ct of

epide

miolo

gical

studie

s14

.1014

.0228

.1214

.3014

.0228

.3214

.3013

.6527

.9514

.8013

.6528

.452.2

Elucid

ate m

echa

nisms

of ca

rcino

gene

sis th

roug

h the

cond

uct o

f labo

rator

y stud

ies6.5

58.4

014

.956.5

58.4

014

.955.3

06.4

011

.705.3

06.4

011

.702.3

Prov

ide ex

pert

evalu

ation

s of t

he av

ailab

le ev

idenc

e-ba

se to

iden

tify hu

man c

arcin

ogen

s3.8

02.5

06.3

03.8

02.5

06.3

03.8

02.5

06.3

03.8

02.5

06.3

024

.4524

.9249

.3724

.6524

.9249

.5723

.4022

.5545

.9523

.9022

.5546

.45

3Ev

aluat

e an

d im

pleme

nt ca

ncer

pre

vent

ion a

nd co

ntro

l str

ateg

ies3.1

Enha

nce u

nder

stand

ing of

inter

venti

ons f

or ca

ncer

prev

entio

n and

contr

ol6.5

51.9

08.4

56.5

51.9

08.4

56.5

52.6

09.1

55.5

52.6

08.1

53.2

Enha

nce t

he im

pleme

ntatio

n of c

ance

r pre

venti

on an

d con

trol p

rogr

amme

s3.7

01.6

05.3

03.7

01.6

05.3

03.3

50.9

54.3

03.3

50.9

54.3

03.3

Prov

ide ex

pert

evalu

ation

s of t

he av

ailab

le ev

idenc

e-ba

se in

orde

r to r

ecom

mend

prev

entio

n stra

tegies

1.20

0.50

1.70

1.20

0.50

1.70

1.20

0.90

2.10

1.20

0.90

2.10

11.45

4.00

15.45

11.45

4.00

15.45

11.10

4.45

15.55

10.10

4.45

14.55

4In

crea

se th

e ca

pacit

y fo

r can

cer r

esea

rch

4.1Inc

reas

e hum

an re

sour

ces f

or ca

ncer

rese

arch

1.00

3.08

4.08

1.00

3.00

4.00

1.00

3.00

4.00

1.00

3.00

4.00

4.2De

velop

new

metho

dolog

ies fo

r can

cer r

esea

rch6.8

05.4

812

.286.0

05.4

811

.487.5

56.4

013

.958.0

56.4

014

.454.3

Prov

ide th

e res

ource

s and

infra

struc

ture t

o sup

port

and e

nhan

ce re

sear

ch4.3

511

.2015

.554.9

511

.2016

.154.9

012

.1017

.004.9

012

.1017

.0012

.1519

.7631

.9111

.9519

.6831

.6313

.4521

.5034

.9513

.9521

.5035

.45

5Pr

ovide

stra

tegic

lead

ersh

ip an

d en

hanc

e th

e im

pact

of t

he A

genc

y’s c

ontr

ibutio

n to

glob

al ca

ncer

rese

arch

5.1De

fine t

he vi

sion a

nd im

pleme

nt the

scien

tific s

trateg

y of t

he A

genc

y, pr

ovidi

ng th

e fra

mewo

rk for

the f

ulfilm

ent o

f its o

bjecti

ves

1.30

1.50

2.80

1.30

1.50

2.80

1.60

1.25

2.85

1.60

1.25

2.85

5.2Ov

erse

e the

stra

tegic

direc

tion o

f the

Age

ncy a

nd th

e imp

lemen

tation

of its

prog

ramm

e0.0

01.0

01.0

00.0

01.0

01.0

00.0

01.0

01.0

00.0

01.0

01.0

05.3

Crea

te an

d main

tain k

ey st

rateg

ic pa

rtner

ships

with

natio

nal, r

egion

al an

d inte

rnati

onal

orga

nizati

ons

0.65

0.30

0.95

0.65

0.30

0.95

1.35

0.50

1.85

1.35

0.50

1.85

5.4Eff

ectiv

ely co

mmun

icate

and d

issem

inate

the w

ork o

f the

Age

ncy

5.00

3.00

8.00

5.00

3.00

8.00

5.00

3.00

8.00

5.00

3.00

8.00

6.95

5.80

12.75

6.95

5.80

12.75

7.95

5.75

13.70

7.95

5.75

13.70

6En

able

and

supp

ort t

he e

fficie

nt co

nduc

t and

coor

dinat

ion o

f res

earc

h6.1

Ensu

re th

e Age

ncy i

s dire

cted a

nd m

anag

ed ac

cord

ing to

high

est s

ector

stan

dard

s11

.3523

.3034

.6511

.3523

.3034

.6511

.4522

.7534

.2011

.4522

.7534

.206.2

Inves

t stra

tegica

lly to

ward

s inc

reas

ing IA

RC’s

capa

city

0.75

0.60

1.35

0.75

0.60

1.35

0.65

0.60

1.25

0.65

0.60

1.25

12.10

23.90

36.00

12.10

23.90

36.00

12.10

23.35

35.45

12.10

23.35

35.45

TOTA

L72

.5085

.7815

8.28

73.10

85.70

158.8

074

.0085

.2015

9.20

74.00

85.20

159.2

0

(exp

ress

ed in

perso

n yea

rs)SU

MMAR

Y OF

REG

ULAR

BUD

GET F

UNDE

D ST

AFF B

Y LE

VEL 2

/3 O

BJEC

TIVE

S AN

D ST

AFF C

ATEG

ORY

Summ

ary

Table

D

2019

Staf

f Acti

vity

(per

son y

ears)

2018

Staf

f Acti

vity

(per

son y

ears)

2016

Staf

f Acti

vity

(per

son y

ears)

2017

Staf

f Acti

vity

(per

son y

ears)


Leve

l 2Le

vel 2

Obj

ectiv

esRE

GULA

R BU

DGET

ARY R

ESOU

RCES

EXTR

A-BU

DGET

ARY R

ESOU

RCES

Leve

l 3Le

vel 3

Obje

ctive

sPr

ofess

ional

and a

bove

Gene

ral

Servi

cePr

ofess

ional

and a

bove

Gene

ral

Servi

ce S

taff B

udge

t 20

18-2

019

Non

-staff

Bu

dget

2018

-201

9 T

otal

2018

-201

9 S

taff B

udge

t 20

18-2

019

Non

-staff

Bu

dget

2018

-201

9 T

otal

2018

-201

9

1De

scrib

e th

e oc

curr

ence

of c

ance

r1.1

Impr

ove a

nd ex

pand

repo

rting

of de

scrip

tive c

ance

r stat

istics

3.90

4.70

3.90

4.70

1,891

,815

180,0

00

2,071

,815

133,1

03

-

133,1

03

1.2Su

ppor

t impr

oved

cove

rage

and q

uality

of ca

ncer

regis

tratio

n, pa

rticu

larly

in low

and m

iddle-

incom

e cou

ntries

(LMI

C)1.1

0

2.3

0

1.1

0

2.3

0

67

7,061

19

0,000

86

7,061

11

3,706

12

1,000

23

4,706

1.3

Impr

ove t

umou

r clas

sifica

tion t

o info

rm ca

ncer

regis

tratio

n, re

sear

ch an

d tre

atmen

t1.0

0

0.6

0

1.0

0

0.6

0

46

2,517

10

6,000

56

8,517

69

4,345

48

6,000

1,1

80,34

5

6.0

0

7.6

0

6.0

0

7.6

0

3,0

31,39

3

47

6,000

3,5

07,39

3

94

1,154

60

7,000

1,5

48,15

4

2Un

ders

tand

the

caus

es o

f can

cer

2.1Ide

ntify

the ri

sk fa

ctors

for hu

man c

ance

r thr

ough

the c

ondu

ct of

epide

miolo

gical

studie

s14

.30

13.65

14

.80

13.65

6,2

94,79

5

87

2,800

7,1

67,59

5

56

6,304

3,1

07,08

2

3,6

73,38

6

2.2

Elucid

ate m

echa

nisms

of ca

rcino

gene

sis th

roug

h the

cond

uct o

f labo

rator

y stud

ies5.3

0

6.4

0

5.3

0

6.4

0

2,4

06,00

2

41

9,400

2,8

25,40

2

25

5,186

36

8,450

62

3,636

2.3

Prov

ide ex

pert

evalu

ation

s of t

he av

ailab

le ev

idenc

e-ba

se to

iden

tify hu

man c

arcin

ogen

s3.8

0

2.5

0

3.8

0

2.5

0

1,5

98,73

7

28

0,000

1,8

78,73

7

1,2

32,34

6

34

9,253

1,5

81,59

9

23

.40

22.55

23

.90

22.55

10

,299,5

34

1,572

,200

11,87

1,734

2,0

53,83

6

3,8

24,78

5

5,8

78,62

1

3Ev

aluat

e an

d im

pleme

nt ca

ncer

pre

vent

ion a

nd co

ntro

l str

ateg

ies3.1

Enha

nce u

nder

stand

ing of

inter

venti

ons f

or ca

ncer

prev

entio

n and

contr

ol6.5

5

2.6

0

5.5

5

2.6

0

2,2

20,64

7

45

5,000

2,6

75,64

7

68

7,604

31

2,657

1,0

00,26

1

3.2

Enha

nce t

he im

pleme

ntatio

n of c

ance

r pre

venti

on an

d con

trol p

rogr

amme

s3.3

5

0.9

5

3.3

5

0.9

5

1,0

77,23

1

12

3,000

1,2

00,23

1

50

0,899

2,1

79,00

0

2,6

79,89

9

3.3

Prov

ide ex

pert

evalu

ation

s of t

he av

ailab

le ev

idenc

e-ba

se in

orde

r to r

ecom

mend

prev

entio

n stra

tegies

1.20

0.90

1.20

0.90

476,2

25

135,0

00

611,2

25

81,36

2

62,28

8

143,6

50

11.10

4.4

5

10

.10

4.45

3,774

,103

713,0

00

4,487

,103

1,269

,865

2,553

,945

3,823

,810

4In

crea

se th

e ca

pacit

y fo

r can

cer r

esea

rch

4.1Inc

reas

e hum

an re

sour

ces f

or ca

ncer

rese

arch

1.00

3.00

1.00

3.00

724,5

71

1,030

,000

1,754

,571

-

684,4

01

684,4

01

4.2De

velop

new

metho

dolog

ies fo

r can

cer r

esea

rch7.5

5

6.4

0

8.0

5

6.4

0

3,2

88,51

3

39

8,200

3,6

86,71

3

12

7,345

16

1,356

28

8,701

4.3

Prov

ide th

e res

ource

s and

infra

struc

ture t

o sup

port

and e

nhan

ce re

sear

ch4.9

0

12

.10

4.90

12.10

3,1

17,42

5

2,9

72,59

4

6,0

90,01

9

26

4,223

26

6,115

53

0,338

13

.45

21.50

13

.95

21.50

7,1

30,50

9

4,4

00,79

4

11

,531,3

03

391,5

68

1,111

,872

1,503

,440

5Pr

ovide

stra

tegic

lead

ersh

ip an

d en

hanc

e th

e im

pact

of t

he A

genc

y’s c

ontr

ibutio

n to

glob

al ca

ncer

rese

arch

5.1De

fine t

he vi

sion a

nd im

pleme

nt the

scien

tific s

trateg

y of t

he A

genc

y, pr

ovidi

ng th

e fra

mewo

rk for

the f

ulfilm

ent o

f its o

bjecti

ves

1.60

1.25

1.60

1.25

809,0

80

550,0

00

1,359

,080

-

-

-

5.2Ov

erse

e the

stra

tegic

direc

tion o

f the

Age

ncy a

nd th

e imp

lemen

tation

of its

prog

ramm

e-

1.00

-

1.0

0

17

9,701

21

9,000

39

8,701

-

-

-

5.3

Crea

te an

d main

tain k

ey st

rateg

ic pa

rtner

ships

with

natio

nal, r

egion

al an

d inte

rnati

onal

orga

nizati

ons

1.35

0.50

1.35

0.50

467,6

75

150,0

00

617,6

75

-

-

-

5.4Eff

ectiv

ely co

mmun

icate

and d

issem

inate

the w

ork o

f the

Age

ncy

5.00

3.00

5.00

3.00

1,883

,289

542,0

00

2,425

,289

898,6

69

100,0

00

998,6

69

7.95

5.75

7.95

5.75

3,339

,745

1,461

,000

4,800

,745

898,6

69

100,0

00

998,6

69

6En

able

and

supp

ort t

he e

fficie

nt co

nduc

t and

coor

dinat

ion o

f res

earc

h6.1

Ensu

re th

e Age

ncy i

s dire

cted a

nd m

anag

ed ac

cord

ing to

high

est s

ector

stan

dard

s11

.45

22.75

11

.45

22.75

6,6

05,58

3

1,7

90,51

6

8,3

96,09

9

1,2

72,84

8

1,2

17,12

6

2,4

89,97

4

6.2

Inves

t stra

tegica

lly to

ward

s inc

reas

ing IA

RC’s

capa

city

0.65

0.60

0.65

0.60

303,9

23

175,0

00

478,9

23

93,17

6

55,20

0

148,3

76

12.10

23

.35

12.10

23

.35

6,909

,506

1,965

,516

8,875

,022

1,366

,024

1,272

,326

2,638

,350

TOTA

L74

.00

85.20

74

.00

85.20

34

,484,7

90

10,58

8,510

45

,073,3

00

6,921

,116

9,469

,928

16,39

1,044

Summ

ary

Table

EAN

ALYS

IS O

F STA

FFIN

G AN

D RE

SOUR

CES

BY LE

VEL 2

/3 O

BJEC

TIVE

S

2018

STA

FF A

CTIV

ITY

2019

STA

FF A

CTIV

ITY

(Staf

f acti

vity e

xpre

ssed

in pe

rson y

ears

and b

udge

t exp

ress

ed in

euro

s)


Desc

riptio

nAm

ount

(e

uros

)

Perc

enta

gein

crea

se/d

ecre

ase

from

201

6-20

17

1.

Budg

et fo

r 201

6-20

1743

,413

,599

2.

Real

pro

gram

me

incr

ease

/ (d

ecre

ase)

482,

550

1.11

%

3.

Incr

ease

/ (d

ecre

ase)

to u

npro

gram

med

rese

rve

00.

00%

4.

Cost

incr

ease

s / (

decr

ease

s) d

ue to

sta

tuto

ry c

osts

and

infla

tion

1,17

7,15

12.

71%

5.

Budg

et fo

r 201

8-20

1945

,073

,300

3.82

%

Sum

mar

y Ta

ble

FSU

MM

ARY

OF

BUDG

ET C

HANG

ES F

ROM

PRE

VIOU

S BI

ENNI

AL

BUDG

ET

(exp

ress

ed in

eur

os)


2016

-201

7 Bu

dget

2018

-201

9 Bu

dget

COM

PONE

NT

2016

2017

2016

-201

720

1820

1920

18-2

019

Prog

ram

me

Cost

Tota

l%

Staf

f Bud

get:

Pro

fess

iona

l9,

973,

518

10,4

66,1

5120

,439

,669

10,8

66,7

0011

,035

,068

21,9

01,7

6748

3,66

397

8,43

51,

462,

098

7.15

% G

ener

al S

ervic

e6,

094,

986

6,31

0,65

412

,405

,640

6,15

9,24

96,

423,

775

12,5

83,0

23(2

1,33

3)19

8,71

617

7,38

31.

43%

Tot

al S

taff

Cost

s16

,068

,504

16,7

76,8

0532

,845

,309

17,0

25,9

4817

,458

,842

34,4

84,7

9046

2,33

01,

177,

151

1,63

9,48

14.

99%

Non-

Staf

f Bud

get:

Tem

pora

ry a

ssist

ance

40,0

0040

,000

80,0

0040

,000

59,0

0099

,000

19,0

000

19,0

0023

.75%

Tem

pora

ry a

dviso

rs (e

xper

ts, n

ot c

omin

g fo

r mee

tings

)12

8,83

512

8,83

525

7,67

012

4,30

012

4,30

024

8,60

0(9

,070

)0

(9,0

70)

-3.5

2%Ot

her c

ontra

ctua

l arr

ange

men

ts (A

PWs,

SSA

s an

d co

nsul

tant

s)19

6,80

019

6,80

039

3,60

020

6,70

019

4,70

040

1,40

07,

800

07,

800

1.98

%M

eetin

gs (t

empo

rary

adv

isors

and

par

ticip

ants

) 23

6,50

030

6,50

054

3,00

033

1,50

032

8,50

066

0,00

011

7,00

00

117,

000

21.5

5%Du

ty tr

avel

(all

cate

gorie

s of

sta

ff in

cludi

ng fe

llow

s)45

9,57

045

9,57

191

9,14

146

2,30

045

9,30

092

1,60

02,

459

02,

459

0.27

%Co

llabo

rativ

e re

sear

ch a

gree

men

ts38

7,53

437

4,66

576

2,19

933

3,40

025

8,40

059

1,80

0(1

70,3

99)

0(1

70,3

99)

-22.

36%

Supp

lies

150,

396

150,

636

301,

032

128,

650

128,

890

257,

540

(43,

492)

0(4

3,49

2)-1

4.45

%Eq

uipm

ent a

nd fu

rnitu

re15

6,85

314

5,85

330

2,70

617

2,96

015

2,99

032

5,95

023

,244

023

,244

7.68

%Fe

llow

ship

s73

4,50

073

4,50

01,

469,

000

756,

900

754,

900

1,51

1,80

042

,800

042

,800

2.91

%Of

fice

serv

ices

152,

100

152,

620

304,

720

145,

300

145,

970

291,

270

(13,

450)

0(1

3,45

0)-4

.41%

Publ

icatio

ns (i

nclu

ding

prin

ting)

110,

050

110,

290

220,

340

176,

700

164,

900

341,

600

121,

260

012

1,26

055

.03%

Libra

ry b

ooks

& p

erio

dica

ls16

2,20

017

2,20

433

4,40

414

3,00

015

3,50

029

6,50

0(3

7,90

4)0

(37,

904)

-11.

33%

Labo

rato

ry m

aint

enan

ce a

nd s

uppl

ies

341,

150

341,

150

682,

300

317,

450

317,

450

634,

900

(47,

400)

0(4

7,40

0)-6

.95%

IT m

aint

enan

ce a

nd li

cenc

es

35,0

0035

,000

70,0

0038

,350

39,8

0078

,150

8,15

00

8,15

011

.64%

Build

ing

serv

ices

1,59

5,37

11,

570,

007

3,16

5,37

81,

570,

000

1,61

3,00

03,

183,

000

17,6

220

17,6

220.

56%

Staf

f Dev

elop

men

t & T

rain

ing

95,0

0095

,000

190,

000

99,0

0090

,800

189,

800

(200

)0

(200

)-0

.11%

Dire

ctor

's De

velo

pmen

t Pro

visio

n22

0,00

018

0,00

040

0,00

020

0,00

020

0,00

040

0,00

00

00

0.00

%Ot

hers

86,4

0086

,400

172,

800

77,8

0077

,800

155,

600

(17,

200)

0(1

7,20

0)-9

.95%

5,28

8,25

95,

280,

031

10,5

68,2

905,

324,

310

5,26

4,20

010

,588

,510

20,2

200

20,2

200.

19%

Unpr

ogra

mm

ed re

serv

e0

00

00

00

00

0.00

%

TOTA

L RE

GULA

R BU

DGET

21,3

56,7

6322

,056

,836

43,4

13,5

9922

,350

,258

22,7

23,0

4245

,073

,300

482,

550

1,17

7,15

11,

659,

701

3.82

%1.

11%

2.71

%3.

82%

Note

: Cau

ses

of b

udge

t cha

nges

are

cla

ssifi

ed in

to tw

o gr

oups

i.e.

due

to p

rogr

amm

atic

requ

irem

ents

('Pr

ogra

mm

e') a

nd d

ue to

cos

t cha

nges

('Co

st').

Sum

mar

y Ta

ble

GSU

MM

ARY

OF

REGU

LAR

BUDG

ET B

Y CO

MPO

NENT

AND

CA

USE

OF IN

CREA

SE/D

ECRE

ASE

(exp

ress

ed in

eur

os)

BIEN

NIAL

INCR

EASE

/(DE

CREA

SE)

2016

-201

7 TO

201

8-20

19(s

ee b

elow

not

e)


LEVE

L 2

OBJE

CTIV

ES20

1620

1720

16-2

017

%20

1820

1920

18-2

019

%

1.

Des

crib

e th

e oc

curr

ence

of c

ance

r1,

518,

695

1,65

1,78

33,

170,

478

7.30

%1,

734,

106

1,77

3,28

73,

507,

393

7.78

%

2.

Und

erst

and

the

caus

es o

f can

cer

6,04

5,37

86,

280,

298

12,3

25,6

7628

.39%

5,84

5,57

96,

026,

155

11,8

71,7

3426

.34%

3.

Eva

luat

e an

d im

plem

ent c

ance

r pre

vent

ion

and

cont

rol s

trate

gies

2,17

8,44

62,

241,

818

4,42

0,26

410

.18%

2,32

8,26

82,

158,

835

4,48

7,10

39.

95%

4.

Incr

ease

the

capa

city

for c

ance

r res

earc

h5,

093,

809

5,18

7,53

810

,281

,347

23.6

8%5,

677,

720

5,85

3,58

311

,531

,303

25.5

8%

5.

Pro

vide

stra

tegi

c le

ader

ship

and

enh

ance

the

impa

ct o

f the

Age

ncy’s

con

tribu

tion

to g

loba

l can

cer r

esea

rch

2,20

5,07

42,

253,

179

4,45

8,25

310

.27%

2,38

8,44

72,

412,

298

4,80

0,74

510

.65%

6.

Ena

ble

and

supp

ort t

he e

fficie

nt c

ondu

ct a

nd c

oord

inat

ion

of re

sear

ch4,

315,

361

4,44

2,22

08,

757,

581

20.1

7%4,

376,

138

4,49

8,88

48,

875,

022

19.6

9%

Tota

l Reg

ular

Bud

get

21,3

56,7

6322

,056

,836

43,4

13,5

9910

0.00

%22

,350

,258

22,7

23,0

4245

,073

,300

100.

00%

PROP

OSED

FIN

ANC

ING:

(see

Sum

mar

y Ta

ble

I)

Gove

rnin

g Co

uncil

Spe

cial F

und

250,

000

250,

000

500,

000

1.15

%0

00

0.00

%

Parti

cipat

ing

Stat

es A

sses

smen

ts21

,106

,763

21,8

06,8

3642

,913

,599

98.8

5%22

,350

,258

22,7

23,0

4245

,073

,300

100.

00%

Sum

mar

y Ta

ble

HSU

MM

ARY

OF

REGU

LAR

BUDG

ET A

ND P

ROPO

SED

FINA

NCIN

G(e

xpre

ssed

in e

uros

)


YEAR

201

8YE

AR 2

019

BIEN

NIUM

BI

ENNI

UM20

18-2

019

2018

-201

920

18-2

019

2016

-201

720

16-2

017

2016

-201

7

Num

ber

30%

of t

he 3

0% o

f the

of70

% o

f the

asse

ssed

70%

of t

heas

sess

edPa

rticip

atin

g St

ates

units

asse

ssed

bud

get

TOT

AL

as

sess

ed b

udge

t T

OTAL

TOT

AL

TOTA

L%

Am

ount

assig

ned

bud

get

in a

ccor

danc

e b

udge

t in

acc

orda

nce

incr

ease

/in

crea

se/

(see

Not

e b

orne

with

the

unit

bor

ne w

ith th

e un

it

decr

ease

(dec

reas

e)1

& 2)

equ

ally

s

yste

m e

qual

ly

sys

tem

(s

ee N

ote

3)

Aust

ralia

262

5,80

726

2,94

388

8,75

063

6,24

526

7,32

990

3,57

41,

792,

324

1,73

7,46

13.

1654

,863

Aust

ria1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Be

lgiu

m1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Br

azil

262

5,80

726

2,94

388

8,75

063

6,24

526

7,32

990

3,57

41,

792,

324

1,73

7,46

154

,863

Cana

da2

625,

807

262,

943

888,

750

636,

245

267,

329

903,

574

1,79

2,32

41,

737,

461

3.16

54,8

63De

nmar

k1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Fi

nlan

d0

625,

807

062

5,80

763

6,24

50

636,

245

1,26

2,05

21,

494,

554

-15.

56

(232

,502

)Fr

ance

462

5,80

752

5,88

91,

151,

696

636,

245

534,

660

1,17

0,90

52,

322,

601

2,22

3,27

54.

4799

,326

Germ

any

462

5,80

752

5,88

91,

151,

696

636,

245

534,

660

1,17

0,90

52,

322,

601

2,22

3,27

54.

4799

,326

Indi

a1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Ire

land

062

5,80

70

625,

807

636,

245

063

6,24

51,

262,

052

1,25

1,64

70.

8310

,405

Italy

262

5,80

726

2,94

388

8,75

063

6,24

526

7,32

990

3,57

41,

792,

324

2,22

3,27

5-1

9.38

(4

30,9

51)

Japa

n8

625,

807

1,05

1,77

91,

677,

586

636,

245

1,06

9,32

01,

705,

565

3,38

3,15

13,

194,

903

5.89

188,

248

Mor

occo

062

5,80

70

625,

807

636,

245

063

6,24

51,

262,

052

00.

001,

262,

052

Neth

erla

nds

162

5,80

713

1,47

375

7,28

063

6,24

513

3,66

676

9,91

11,

527,

191

1,49

4,55

42.

1832

,637

Norw

ay1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Qa

tar

062

5,80

70

625,

807

636,

245

063

6,24

51,

262,

052

1,25

1,64

710

,405

Repu

blic

of K

orea

262

5,80

726

2,94

388

8,75

063

6,24

526

7,32

990

3,57

41,

792,

324

1,49

4,55

419

.92

297,

770

Russ

ian

Fede

ratio

n2

625,

807

262,

943

888,

750

636,

245

267,

329

903,

574

1,79

2,32

41,

737,

461

3.16

54,8

63Sp

ain

262

5,80

726

2,94

388

8,75

063

6,24

526

7,32

990

3,57

41,

792,

324

1,73

7,46

13.

1654

,863

Swed

en1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Sw

itzer

land

162

5,80

713

1,47

375

7,28

063

6,24

513

3,66

676

9,91

11,

527,

191

1,49

4,55

42.

1832

,637

Turk

ey1

625,

807

131,

473

757,

280

636,

245

133,

666

769,

911

1,52

7,19

11,

494,

554

2.18

32,6

37Un

ited

King

dom

462

5,80

752

5,88

91,

151,

696

636,

245

534,

660

1,17

0,90

52,

322,

601

2,22

3,27

54.

4799

,326

Unite

d St

ates

of A

mer

ica8

625,

807

1,05

1,77

91,

677,

586

636,

245

1,06

9,32

01,

705,

565

3,38

3,15

13,

194,

903

5.89

188,

248

TOTA

L PA

RTIC

IPAT

ING

STAT

ES

5115

,645

,175

6,70

5,08

322

,350

,258

15,9

06,1

256,

816,

917

22,7

23,0

4245

,073

,300

42,9

13,5

995.

032,

159,

701

TOTA

L GC

SF0

00

500,

000

-100

.00

(500

,000

)

TOTA

L FU

NDIN

G15

,645

,175

6,70

5,08

322

,350

,258

15,9

06,1

256,

816,

917

22,7

23,0

4245

,073

,300

43,4

13,5

993.

821,

659,

701

Note

s:1.

The

met

hod

of a

sses

smen

t of c

ontri

butio

ns o

f Par

ticip

atin

g St

ates

is d

etai

led

in R

esol

utio

ns G

C/15

/R9,

GC/

37/R

9, a

nd G

C/56

/R6.

2. G

roup

cla

ssifi

catio

n of

cou

ntrie

s fo

r the

pur

pose

of a

ssig

ning

uni

ts in

acc

orda

nce

with

the

appl

icabl

e GC

reso

lutio

ns is

bas

ed o

n th

e re

vised

sca

le o

f ass

essm

ents

for W

HO s

tarti

ng 2

017

as a

dopt

ed b

y

the

Wor

ld H

ealth

Ass

embl

y in

May

201

6 (W

HA69

.14)

.3.

Mor

occo

's co

ntrib

utio

n is

inclu

ded

in th

e 5.

03%

incr

ease

s in

the

over

all a

sses

smen

t on

Parti

cipat

ing

Stat

es fo

r 201

8-20

19. W

hen

exclu

ding

Mor

occo

, ove

rall

asse

ssm

ent i

ncre

ase

is 2.

09%

, par

tly to

Sum

mar

y Ta

ble

ISU

MM

ARY

OF

PROP

OSED

FIN

ANC

ING

FROM

ASS

ESSM

ENTS

ON

PART

ICIP

ATI

NG S

TATE

S A

ND G

OVER

NING

COU

NCIL

SPE

CIA

L FU

ND(e

xpre

ssed

in e

uros

)

a

bsor

b an

abs

ence

of t

he G

over

ning

Cou

ncil

Spec

ial F

und

(GCS

F).

Scientific Council SC/53/9 Rev.1 Proposed Programme and Budget 2018–2019 (Revision 1) Page 33 ANNEXES

Seven additional tables are also provided hereafter as supplementary information:

• Information Table A - Total staff and non-staff budget by Section and Group: Provides details of staff and non-staff budget annual allocation by Section and Group.

• Information Table B - United Nations accounting rates of exchange: euros to US dollars: Contains the monthly exchange rates set by the United Nations for euros to US dollars from January 2006 to December 2016.

• Information Table C - IARC Project Tree structure and associated projects: Shows the structure of the IARC Project Tree from the highest level objective (level 1) to the most detailed level objectives (level 4) and associated projects contributing to the respective Project Tree path.

• Information Table D - Group classification of countries and assigning units for assessed contributions: Provides supplementary information to the Summary Table I for comparison of the group classification and unit assignment of IARC Participating States in the proposed budget 2018–2019 with three prior approved biennial budgets.

• Information Table E - Comparison of assessments on Participating States based on current and revised scales: Illustrates the assessments on Participating States should the same scale of assessment used for the approved budget 2016–2017 be applied to the proposed budget 2018–2019 in comparison to the assessments based on the revised scale.

• Information Table F - Comparison of proposed regular budget 2018–2019 with approved regular budget 2016–2017 by level 2/3 objectives: Provides supplementary information to the Summary Table B for comparison of the proposed budget 2018–2019 with the approved budget 2016–2017 in equivalent categories of objectives.

• Information Table G - Priority projects requiring additional voluntary contributions: Provides supplementary information to section 3.3 Extrabudgetary resources.


Sec

tion

Gro

up

Sta

ff Bu

dget

Non

-sta

ff Bu

dget

Grou

p To

tal B

udge

tSe

ctio

n To

tal B

udge

t S

taff

Budg

et N

on-s

taff

Budg

etGr

oup

Tota

l Bud

get

Sect

ion

Tota

l Bud

get

Sta

ff Bu

dget

Non

-sta

ff Bu

dget

Grou

p To

tal B

udge

tSe

ctio

n To

tal B

udge

t

Scie

ntifi

c Pr

ogra

mm

e (O

bjec

tive

1-5)

CSU

CSU

1,26

7,08

618

5,00

01,

452,

086

1,45

2,08

61,

301,

790

185,

000

1,48

6,79

01,

486,

790

2,56

8,87

637

0,00

02,

938,

876

2,93

8,87

6

DIR

DI

R 65

0,18

854

5,00

01,

195,

188

1,19

5,18

865

9,44

554

5,00

01,

204,

445

1,20

4,44

51,

309,

633

1,09

0,00

02,

399,

633

2,39

9,63

3

DIR

Oth

ers

COM

99

8,38

327

6,06

01,

274,

443

3,23

0,96

41,

022,

466

265,

940

1,28

8,40

63,

073,

828

2,02

0,84

954

2,00

02,

562,

849

6,30

4,79

2ET

R 35

6,28

651

5,00

087

1,28

636

8,28

551

5,00

088

3,28

572

4,57

11,

030,

000

1,75

4,57

1GH

IS

124,

484

120,

000

244,

484

40,0

0040

,000

124,

484

160,

000

284,

484

LSB

613,

751

227,

000

840,

751

635,

137

227,

000

862,

137

1,24

8,88

845

4,00

01,

702,

888

EDP

PR

I 69

2,71

190

,000

782,

711

1,32

2,55

970

6,02

790

,000

796,

027

1,34

5,93

41,

398,

738

180,

000

1,57

8,73

82,

668,

493

SCR

449,

848

90,0

0053

9,84

845

9,90

790

,000

549,

907

909,

755

180,

000

1,08

9,75

5

ENV

EN

V 1,

088,

794

180,

000

1,26

8,79

41,

268,

794

1,11

5,38

518

0,00

01,

295,

385

1,29

5,38

52,

204,

179

360,

000

2,56

4,17

92,

564,

179

GEN

GC

S 90

7,28

712

8,00

01,

035,

287

1,82

0,95

593

1,23

012

8,00

01,

059,

230

1,86

1,88

91,

838,

517

256,

000

2,09

4,51

73,

682,

844

GEP

678,

668

107,

000

785,

668

695,

659

107,

000

802,

659

1,37

4,32

721

4,00

01,

588,

327

IMO

IMO

1,18

7,50

426

0,50

01,

448,

004

1,44

8,00

41,

212,

415

260,

500

1,47

2,91

51,

472,

915

2,39

9,91

952

1,00

02,

920,

919

2,92

0,91

9

INF

ICB

604,

152

95,0

0069

9,15

21,

664,

755

619,

864

95,0

0071

4,86

41,

700,

507

1,22

4,01

619

0,00

01,

414,

016

3,36

5,26

2IC

E 87

0,60

395

,000

965,

603

890,

643

95,0

0098

5,64

31,

761,

246

190,

000

1,95

1,24

6

MCA

EG

E 57

6,42

295

,000

671,

422

1,35

3,04

759

3,45

695

,000

688,

456

1,38

5,16

01,

169,

878

190,

000

1,35

9,87

82,

738,

207

MM

B58

6,62

595

,000

681,

625

601,

704

95,0

0069

6,70

41,

188,

329

190,

000

1,37

8,32

9

NM

E BM

A69

6,28

761

,000

757,

287

1,82

1,52

282

8,19

261

,000

889,

192

1,96

1,79

91,

524,

479

122,

000

1,64

6,47

93,

783,

321

NEP

555,

749

75,0

0063

0,74

956

6,56

461

,000

627,

564

1,12

2,31

313

6,00

01,

258,

313

NMB

372,

486

61,0

0043

3,48

638

4,04

361

,000

445,

043

756,

529

122,

000

878,

529

SSR

ASO/

ITS

258,

002

940,

750

1,19

8,75

21,

198,

752

268,

055

966,

244

1,23

4,29

91,

234,

299

526,

057

1,90

6,99

42,

433,

051

2,43

3,05

1

SSR

DAF

(GCG

/SCI

)87

,994

109,

500

197,

494

197,

494

91,7

0710

9,50

020

1,20

720

1,20

717

9,70

121

9,00

039

8,70

139

8,70

1

Adm

inis

trat

ive

Prog

ram

me

(Obj

ectiv

e 6)

SSR

ASO

984,

432

779,

500

1,76

3,93

24,

376,

138

1,02

2,57

879

8,01

61,

820,

594

4,49

8,88

42,

007,

011

1,57

7,51

63,

584,

527

8,87

5,02

2BF

O1,

136,

181

29,0

001,

165,

181

1,16

7,87

329

,000

1,19

6,87

32,

304,

054

58,0

002,

362,

054

DAF

402,

493

10,5

0041

2,99

341

1,25

810

,500

421,

758

813,

751

21,0

0083

4,75

1HR

O47

3,62

391

,500

565,

123

490,

082

91,5

0058

1,58

296

3,70

518

3,00

01,

146,

705

ITS

405,

909

63,0

0046

8,90

941

5,07

663

,000

478,

076

820,

985

126,

000

946,

985

TOTA

L 17

,025

,948

5,32

4,31

022

,350

,258

22,3

50,2

5817

,458

,842

5,26

4,20

022

,723

,042

22,7

23,0

4234

,484

,790

10,5

88,5

1045

,073

,300

45,0

73,3

00

Info

rmat

ion

Tabl

e A

TOTA

L ST

AFF

AND

NON

-STA

FF B

UDGE

T BY

SEC

TION

AND

GRO

UP(e

xpre

ssed

in e

uros

)

2018

2019

2018

-201

9


2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

Janu

ary

0.84

50.

760

0.68

60.

730

0.69

30.

761

0.77

40.

754

0.72

50.

850

0.92

2

Febr

uary

0.82

70.

771

0.67

60.

762

0.71

40.

734

0.76

30.

737

0.73

70.

882

0.88

2

Mar

ch0.

844

0.75

50.

661

0.78

20.

741

0.72

80.

746

0.77

30.

731

0.94

30.

895

April

0.82

70.

750

0.63

40.

759

0.74

30.

710

0.75

30.

783

0.72

70.

923

0.88

7

May

0.79

10.

732

0.64

20.

744

0.77

40.

675

0.75

50.

764

0.72

30.

904

0.88

2

June

0.77

80.

744

0.64

30.

717

0.81

90.

702

0.80

50.

767

0.73

50.

894

0.89

7

July

0.79

60.

740

0.63

60.

711

0.81

10.

699

0.80

40.

767

0.73

60.

905

0.90

1

Augu

st0.

784

0.73

10.

658

0.71

20.

763

0.70

00.

816

0.75

40.

748

0.91

50.

895

Sept

embe

r0.

780

0.73

40.

698

0.69

50.

787

0.68

80.

797

0.75

50.

759

0.88

90.

897

Octo

ber

0.78

80.

705

0.72

90.

688

0.73

50.

733

0.77

70.

737

0.78

70.

891

0.90

6

Nove

mbe

r0.

786

0.69

40.

773

0.67

60.

720

0.70

70.

772

0.72

60.

803

0.91

20.

920

Dece

mbe

r0.

759

0.67

80.

758

0.66

40.

764

0.75

00.

770

0.73

60.

820

0.91

40.

942

Annu

al A

vera

ge0.

800

0.73

30.

683

0.72

00.

755

0.71

60.

778

0.75

40.

753

0.90

20.

902

Bien

nial

Ave

rage

0.76

70.

701

0.73

50.

766

0.82

720

06/2

007

2008

/200

920

10/2

011

2012

/201

320

14/2

015

Budg

et 2

006/

2007

app

rove

d at

0.8

15 €

/US$

Budg

et 2

010/

2011

app

rove

d at

0.6

60 €

/US$

Budg

et 2

014/

2015

app

rove

d at

0.7

58 €

/US$

Budg

et 2

008/

2009

app

rove

d at

0.8

15 €

/US$

Budg

et 2

012/

2013

app

rove

d at

0.6

75 €

/US$

Budg

et 2

016/

2017

app

rove

d at

0.7

29 €

/US$

Info

rmat

ion

Tabl

e B

UNIT

ED N

ATI

ONS

ACC

OUNT

ING

RATE

S OF

EXC

HANG

E: E

UROS

TO

US D

OLLA

RSFr

om Ja

nuar

y 20

06 to

Dec

embe

r 201

6


Le

vel 2

/3 O

bjec

tives

Le

vel 4

Obj

ectiv

esPr

ojec

t Num

ber

Proj

ect T

itle

1De

scrib

e th

e oc

curr

ence

of c

ance

r1.

1Im

prov

e an

d ex

pand

repo

rting

of d

escr

iptiv

e ca

ncer

sta

tistic

s1.

1.1

Expa

nd th

e de

scrip

tive

anal

yses

of c

ance

r inc

iden

ce, m

orta

lity,

pr

eval

ence

and

sur

vival

regi

onal

ly an

d w

orld

wid

ePB

.181

9.CS

U.03

Desc

riptiv

e ep

idem

iolo

gy o

f can

cer

1.1.

2Im

prov

e th

e va

lidity

, ran

ge, t

imel

ines

s an

d di

ssem

inat

ion

of

appr

opria

te c

ance

r ind

icato

rs a

vaila

ble

at th

e na

tiona

l, re

gion

al

and

glob

al le

vel

PB.1

819.

CSU.

01Gl

obal

can

cer i

ndica

tors

: dev

elop

men

t and

diss

emin

atio

n

1.2

Supp

ort i

mpr

oved

cov

erag

e an

d qu

ality

of c

ance

r reg

istra

tion,

pa

rticu

larly

in lo

w a

nd m

iddl

e-in

com

e co

untri

es (L

MIC

)1.

2.1

Impr

ove

the

avai

labi

lity,

qua

lity

and

diss

emin

atio

n of

regi

stry

dat

a,

via IA

RC R

egio

nal H

ubs

and

prom

ote

the

role

of p

opul

atio

n-ba

sed

canc

er re

gist

ries

in c

ance

r con

trol p

lann

ing

PB.1

819.

CSU.

02Ca

ncer

regi

stry

sup

port

and

deve

lopm

ent

1.3

Impr

ove

tum

our c

lass

ifica

tion

to in

form

can

cer r

egist

ratio

n,

rese

arch

and

trea

tmen

t1.

3.1

Publ

ish W

HO C

lass

ifica

tion

of T

umou

rs S

erie

sPB

.181

9.IM

O.03

WHO

cla

ssifi

catio

n of

tum

ours

ser

ies

2Un

ders

tand

the

cau

ses

of c

ance

r2.

12.

1.1

Adva

nce

unde

rsta

ndin

g of

the

role

of i

nfec

tious

age

nts

PB.1

819.

ICB.

02De

term

ine

the

role

of i

nfec

tious

age

nts

in d

iffer

ent h

uman

can

cers

PB.1

819.

ICE.

02Sp

ectru

m, n

atur

al h

istor

y, a

nd p

reve

ntio

n of

infe

ctio

n-as

socia

ted

canc

ers

2.1.

2PB

.181

9.EN

V.01

To s

tudy

car

cinog

enic

effe

cts

of e

xpos

ure

to p

rotra

cted

low

dos

es o

f ion

ising

radi

atio

nPB

.181

9.EN

V.02

To s

tudy

exp

osur

e to

non

-ioni

sing

radi

atio

n (e

lect

rom

agne

tic fi

elds

)PB

.181

9.EN

V.03

To s

tudy

can

cers

with

sus

pect

ed e

nviro

nmen

tal,

occu

patio

nal o

r life

style

-rel

ated

cau

ses

PB.1

819.

ENV.

04To

stu

dy u

niqu

e en

viron

men

tal,

lifes

tyle

and

occ

upat

iona

l exp

osur

es

2.1.

3PB

.181

9.BM

A.01

Diet

ary

and

met

abol

ic bi

omar

kers

ass

ocia

ted

with

can

cer a

nd in

term

edia

te e

nd-p

oint

sPB

.181

9.NE

P.01

Mol

ecul

ar e

pide

mio

logi

c st

udie

s of

nut

ritio

n an

d m

etab

olism

and

can

cer

PB.1

819.

NMB.

02Di

etar

y an

d lif

esty

le e

xpos

ures

ass

ocia

ted

with

can

cer a

nd o

ther

non

-com

mun

icabl

e di

seas

es2.

1.4

PB.1

819.

GCS.

01Id

entif

y ge

nes

invo

lved

in c

ance

r dev

elop

men

tPB

.181

9.GE

P.01

Gene

tic e

pide

mio

logy

of t

obac

co a

nd a

lcoho

l rel

ated

can

cer

PB.1

819.

GEP.

02Ki

dney

can

cer m

olec

ular

epi

dem

iolo

gy2.

22.

2.1

Adva

nce

unde

rsta

ndin

g of

bio

logi

cal a

nd c

ellu

lar p

athw

ays

dli

i

iPB

.181

9.EG

E.01

Epig

enet

ic al

tera

tions

in s

tudi

es o

f can

cer c

ausa

tion

and

prev

entio

n

PB.1

819.

ICB.

01Bi

olog

ical p

rope

rties

of i

nfec

tious

age

nts

in in

vitr

o an

d in

vivo

exp

erim

enta

l mod

els

PB.1

819.

MM

B.01

Som

atic

alte

ratio

ns a

nd m

echa

nism

s of

car

cinog

enes

is as

socia

ted

with

exp

osur

e to

env

ironm

enta

l risk

fa

ctor

s2.

2.2

PB.1

819.

EGE.

02Ep

igen

etics

-bas

ed b

iom

arke

rs in

exp

osom

icsPB

.181

9.M

MB.

02M

olec

ular

alte

ratio

ns a

s bi

omar

kers

of e

xpos

ure,

can

cer r

isk a

nd d

etec

tion

2.3

Prov

ide

expe

rt ev

alua

tions

of t

he a

vaila

ble

evid

ence

-bas

e to

id

entif

y hu

man

car

cinog

ens

2.3.

1Pu

blish

IARC

Mon

ogra

phs

and

asso

ciate

d ou

tput

s on

stra

tegi

cally

re

late

d to

pics

PB.1

819.

IMO.

01IA

RC M

onog

raph

s on

the

Eval

uatio

n of

Car

cinog

enic

Risk

s to

Hum

ans

3 3.1

3.1.

1An

alys

e th

e ef

ficac

y of

prim

ary

canc

er p

reve

ntio

n st

rate

gies

PB.1

819.

GHI.0

1Ga

mbi

a He

patit

is In

terv

entio

n St

udy

(GHI

S)PB

.181

9.IC

E.01

Impl

emen

tatio

n an

d m

onito

ring

of H

PV v

accin

atio

n an

d HP

V-ba

sed

scre

enin

g in

low

and

mid

dle-

inco

me

coun

tries

PB.1

819.

PRI.0

3Ep

idem

iolo

gy a

nd p

reve

ntio

n of

gas

tric

canc

er3.

1.2

Anal

yse

the

effic

acy

of s

econ

dary

can

cer p

reve

ntio

n st

rate

gies

PB.1

819.

PRI.0

2Ce

rvica

l can

cer s

cree

ning

stra

tegi

es fo

r low

and

mid

dle

inco

me

coun

tries

3.1.

3En

hanc

e un

ders

tand

ing

of th

e fa

ctor

s af

fect

ing

canc

er p

rogn

osis

PB.1

819.

ENV.

05To

stu

dy li

fest

yle a

nd e

nviro

nmen

tal d

eter

min

ants

of c

ance

r risk

s, p

rogn

osis

and

canc

er o

utco

mes

PB.1

819.

SCR.

03Im

prov

ing

the

qual

ity o

f bre

ast c

ance

r scr

eeni

ng, e

arly

diag

nosis

and

trea

tmen

t ser

vices

in L

MIC

s3.

23.

2.1

PB.1

819.

ENV.

06Ex

pans

ion

and

eval

uatio

n of

Can

cer P

reve

ntio

n Re

com

men

datio

nsPB

.181

9.PR

I.01

Impl

emen

tatio

n st

udie

s of

HPV

vac

cinat

ion

PB.1

819.

SCR.

01Ev

alua

tion

of c

ervic

al c

ance

r con

trol m

easu

res

in d

evel

opin

g co

untri

esPB

.181

9.SC

R.02

Eval

uatio

n of

col

orec

tal a

nd o

ral c

ance

r scr

eeni

ngPB

.181

9.SC

R.04

Canc

er S

cree

ning

Initi

ative

s &

Thei

r Im

pact

in 5

Con

tinen

ts3.

3Pr

ovid

e ex

pert

eval

uatio

ns o

f the

ava

ilabl

e ev

iden

ce-b

ase

in o

rder

to

reco

mm

end

prev

entio

n st

rate

gies

3.3.

1Pu

blish

IARC

Han

dboo

ks o

n Ca

ncer

Pre

vent

ion

PB.1

819.

IMO.

02IA

RC H

andb

ooks

of C

ance

r Pre

vent

ion

Eluc

idat

e m

echa

nism

s of

car

cinog

enes

is th

roug

h th

e co

nduc

t of

labo

rato

ry s

tudi

es

Iden

tify

the

risk

fact

ors

for h

uman

can

cer t

hrou

gh th

e co

nduc

t of

epid

emio

logi

cal s

tudi

es

Adva

nce

unde

rsta

ndin

g of

the

role

of g

enet

ic fa

ctor

s in

influ

encin

g ris

k, a

nd th

eir i

nter

actio

n w

ith n

on-g

enet

ic fa

ctor

s

Adva

nce

unde

rsta

ndin

g of

the

role

of d

ieta

ry, m

etab

olic

and

lifes

tyle

fact

ors

Info

rmat

ion

Tabl

e C

IARC

PRO

JECT

TRE

E ST

RUCT

URE

AND

ASS

OCIA

TED

PROJ

ECTS

LE

VEL

1 OB

JECT

IVE:

Red

uce

the

burd

en o

f can

cer

wor

ldw

ide

thro

ugh

the

cond

uct

of r

esea

rch

Adva

nce

unde

rsta

ndin

g of

the

role

of e

nviro

nmen

tal,

occu

patio

nal

and

iatro

geni

c fa

ctor

s

Appl

y bi

omar

kers

to s

tudi

es o

f can

cer c

ause

s an

d m

olec

ular

ge

netic

cla

ssifi

catio

n of

tum

ours

Iden

tify

fact

ors

influ

encin

g th

e ef

fect

ive im

plem

enta

tion

of p

rimar

y an

d se

cond

ary

prev

entio

n pr

ogra

mm

esEn

hanc

e th

e im

plem

enta

tion

of c

ance

r pre

vent

ion

and

cont

rol

prog

ram

mes

Enha

nce

unde

rsta

ndin

g of

inte

rven

tions

for c

ance

r pre

vent

ion

and

cont

rol

Eval

uate

and

impl

emen

t ca

ncer

pre

vent

ion

and

cont

rol s

trat

egie

s


Le

vel 2

/3 O

bjec

tives

Le

vel 4

Obj

ectiv

esPr

ojec

t Num

ber

Proj

ect T

itle

4 4.1

Incr

ease

hum

an re

sour

ces

for c

ance

r res

earc

h4.

1.1

Awar

d fe

llow

ship

s an

d pr

ovid

e tra

inin

g th

roug

h pa

rticip

atio

n in

co

llabo

rativ

e re

sear

ch p

roje

cts

PB.1

819.

ETR.

01IA

RC R

esea

rch

Trai

ning

and

Fel

low

ship

Pro

gram

me

4.1.

2De

liver

trai

ning

cou

rses

, bas

ic an

d ad

vanc

ed, i

n th

e ar

eas

of c

ore

com

pete

ncie

s of

the

Agen

cyPB

.181

9.ET

R.02

IARC

Cou

rses

4.2

Deve

lop

new

met

hodo

logi

es fo

r can

cer r

esea

rch

4.2.

1PB

.181

9.EN

V.07

Cont

ribut

e to

adv

ance

d bi

osta

tistic

al a

nalys

es a

nd d

evel

opin

g bi

osta

tistic

al m

etho

dsPB

.181

9.IC

E.03

Impr

ovin

g st

atist

ical m

etho

ds a

nd m

odel

s to

est

imat

e in

fect

ion-

asso

ciate

d ca

ncer

s PB

.181

9.NM

B.01

Inte

grat

ion

of li

fest

yle a

nd –

omics

-bas

ed e

xpos

ures

in a

etio

logi

cal m

odel

s fo

r can

cer r

esea

rch

4.2.

2Im

prov

e an

d im

plem

ent l

abor

ator

y m

etho

dsPB

.181

9.BM

A.02

Met

abol

omics

-bas

ed d

evel

opm

ent o

f bio

mar

kers

of f

oods

, foo

d co

nstit

uten

ts, f

ood

cont

amin

ants

and

m

etab

olism

PB.1

819.

EGE.

03Ep

igen

omic

prof

iling

appl

icabl

e to

mol

ecul

ar e

pide

mio

logy

PB.1

819.

GCS.

02No

n-in

vasiv

e bi

omar

kers

for e

arly

dete

ctio

n of

can

cer

PB.1

819.

MM

B.03

Expe

rimen

tal m

etho

dolo

gies

and

bio

info

rmat

ic re

sour

ces

for m

olec

ular

can

cer r

esea

rch

PB.1

819.

NEP.

02No

vel t

ools

and

plat

form

s fo

r nut

ritio

n as

sess

men

t in

canc

er e

pide

mio

logy

4.3

4.3.

1De

velo

p an

d m

aint

ain

rese

arch

pla

tform

sPB

.181

9.GE

P.03

Coor

dina

tion

of la

rge

coho

rt st

udie

s as

rese

arch

pla

tform

sPB

.181

9.LS

B.01

Man

agem

ent o

f IAR

C bi

oban

k an

d pr

e-an

alyt

ical p

roce

ssin

g se

rvice

sPB

.181

9.LS

B.03

Capa

city

build

ing

and

biob

ank

infra

stru

ctur

e su

ppor

t for

Low

and

Mid

dle

Inco

me

Coun

tries

(LM

IC)

4.3.

2De

velo

p an

d m

aint

ain

labo

rato

ry a

nd c

ompu

ting

serv

ices

PB.1

819.

GCS.

03Ge

netic

s Pl

atfo

rmPB

.181

9.LS

B.02

Labo

rato

ry S

ervic

es s

uppo

rtPB

.181

9.LS

B.04

Hist

olog

y la

bora

tory

PB.1

819.

MM

B.04

The

IARC

TP5

3 Da

taba

sePB

.181

9.SS

R.03

Labo

rato

ry a

nd c

ompu

ting

serv

ices

4.3.

3Re

spon

d to

em

ergi

ng re

sear

ch o

ppor

tuni

ties

and

dem

ands

by

supp

ortin

g ne

w o

r ong

oing

initi

ative

sPB

.181

9.DI

R.03

Stra

tegi

c Re

sear

ch In

vest

men

t

5 5.1

Defin

e th

e vis

ion

and

impl

emen

t the

scie

ntifi

c st

rate

gy o

f the

Ag

ency

, pro

vidin

g th

e fra

mew

ork

for t

he fu

lfilm

ent o

f its

obj

ectiv

es5.

1.1

Defin

e th

e vis

ion

and

impl

emen

t the

scie

ntifi

c st

rate

gy o

f the

Ag

ency

, pro

vidin

g th

e fra

mew

ork

for t

he fu

lfilm

ent o

f its

obj

ectiv

es

PB.1

819.

DIR.

01Di

rect

ion

and

Lead

ersh

ip

5.2

Over

see

the

stra

tegi

c di

rect

ion

of th

e Ag

ency

and

the

impl

emen

tatio

n of

its

prog

ram

me

5.2.

1Ov

erse

e th

e st

rate

gic

dire

ctio

n of

the

Agen

cy a

nd th

e im

plem

enta

tion

of it

s pr

ogra

mm

ePB

.181

9.SS

R.05

Supp

ort t

o Go

vern

ing

and

Scie

ntifi

c Co

uncil

mee

tings

and

inte

ract

ions

with

Par

ticip

atin

g St

ates

5.3

Crea

te a

nd m

aint

ain

key

stra

tegi

c pa

rtner

ship

s w

ith n

atio

nal,

regi

onal

and

inte

rnat

iona

l org

aniza

tions

5.3.

1Cr

eate

and

mai

ntai

n ke

y st

rate

gic

partn

ersh

ips

with

nat

iona

l, re

gion

al a

nd in

tern

atio

nal o

rgan

izatio

nsPB

.181

9.DI

R.02

Stra

tegi

c Pa

rtner

ship

s

5.4

Effe

ctive

ly co

mm

unica

te a

nd d

issem

inat

e th

e w

ork

of th

e Ag

ency

5.4.

1Ef

fect

ively

com

mun

icate

and

diss

emin

ate

the

wor

k of

the

Agen

cyPB

.181

9.CO

M.0

1In

form

atio

n Se

rvice

s an

d Di

ssem

inat

ion

PB.1

819.

COM

.02

Editi

ng, L

ayou

t, an

d Tr

ansla

tion

PB.1

819.

COM

.03

Web

Ser

vices

PB.1

819.

COM

.04

Med

ia R

elat

ions

and

Mul

timed

ia

6 6.1

6.1.

1Pr

ovid

e so

und

man

agem

ent o

f hum

an a

nd in

frast

ruct

ure

reso

urce

sPB

.181

9.SS

R.01

Soun

d m

anag

emen

t of h

uman

and

infra

stru

ctur

e re

sour

ces

PB.1

819.

SSR.

06No

uvea

u Ce

ntre

6.1.

2En

sure

the

fund

ing

requ

irem

ents

for t

he A

genc

y’s a

ctivi

ties

are

met

an

d av

aila

ble

reso

urce

s ar

e di

sbur

sed

in li

ne w

ith th

e st

rate

gy

PB.1

819.

SSR.

02Fi

nanc

ial m

anag

emen

t in

line

with

the

stra

tegy

6.2

Inve

st s

trate

gica

lly to

war

ds in

crea

sing

IARC

’s ca

pacit

y 6.

2.1

Ensu

re a

wor

k cu

lture

that

enc

oura

ges

expl

orin

g ne

w a

ppro

ache

s an

d op

portu

nitie

sPB

.181

9.SS

R.04

Wor

k cu

lture

to e

ncou

rage

new

app

roac

hes

and

oppo

rtuni

ties

Prov

ide

the

reso

urce

s an

d in

frast

ruct

ure

to s

uppo

rt an

d en

hanc

e re

sear

ch

Enab

le a

nd s

uppo

rt t

he e

ffic

ient

con

duct

and

coo

rdin

atio

n of

res

earc

hImpr

ove

and

impl

emen

t epi

dem

iolo

gica

l, st

atist

ical a

nd

bioi

nfor

mat

ics m

etho

ds

Ensu

re th

e Ag

ency

is d

irect

ed a

nd m

anag

ed a

ccor

ding

to h

ighe

st

sect

or s

tand

ards

Incr

ease

the

cap

acity

for

canc

er r

esea

rch

Prov

ide

stra

tegi

c le

ader

ship

and

enh

ance

the

impa

ct o

f the

Age

ncy’

s co

ntrib

utio

n to

glo

bal c

ance

r re

sear

ch


WHO

's %

Co

ntrib

utio

nIA

RC G

roup

IARC

Sca

le

(# u

nits

)

8%

and

abo

ve1

8

4%

and

abo

ve; b

elow

8%

24

2

% a

nd a

bove

; bel

ow 4

%3

2

0.5

% a

nd a

bove

; bel

ow 2

%4

1

less

than

0.5

%5

0

WHO

's

% C

ontri

butio

nIA

RC G

roup

IARC

Sca

le

(# u

nits

)W

HO's

%

Con

tribu

tion

IARC

Gro

upIA

RC S

cale

(#

uni

ts)

WHO

's

% C

ontri

butio

nIA

RC G

roup

IARC

Sca

le

(# u

nits

)W

HO's

%

Con

tribu

tion

IARC

Gro

upIA

RC S

cale

(#

uni

ts)

Aust

ralia

2.33

713

22.

0741

32

2.07

413

21.

9331

41

Aust

ria0.

7201

41

0.79

814

10.

7981

41

0.85

114

1Be

lgiu

m0.

8851

41

0.99

814

10.

9981

41

1.07

514

1Br

azil

3.82

323

22.

9342

32

2.93

423

21.

6111

41

Cana

da2.

9211

32

2.98

423

22.

9842

32

3.20

723

2De

nmar

k0.

5840

41

0.67

504

10.

6750

41

0.73

614

1Fi

nlan

d0.

4560

50

0.51

904

10.

5190

41

0.56

604

1Fr

ance

4.85

922

45.

5935

24

5.59

352

46.

1234

24

Germ

any

6.38

922

47.

1416

24

7.14

162

48.

0186

18

Indi

a0.

7370

41

0.66

604

10.

6660

41

0.53

404

1Ire

land

0.33

505

00.

4180

50

0.41

805

00.

4980

50

Italy

3.74

823

24.

4483

24

4.44

832

44.

9994

24

Japa

n9.

6802

18

10.8

338

18

10.8

338

18

12.5

309

18

Mor

occo

0.05

405

00.

0620

50

0.06

205

00.

0580

50

Neth

erla

nds

1.48

214

11.

6541

41

1.65

414

11.

8551

41

Norw

ay0.

8491

41

0.85

114

10.

8511

41

0.87

114

1Qa

tar

0.26

905

00.

2090

50

0.20

905

00.

1350

50

Repu

blic

of K

orea

2.03

913

21.

9941

41

1.99

414

12.

2602

32

Russ

ian

Fede

ratio

n3.

0882

32

2.43

823

22.

4382

32

1.60

214

1Sp

ain

2.44

313

22.

9732

32

2.97

323

23.

1772

32

Swed

en0.

9561

41

0.96

014

10.

9601

41

1.06

414

1Sw

itzer

land

1.14

014

11.

0471

41

1.04

714

11.

1301

41

Turk

ey1.

0181

41

1.32

814

11.

3281

41

0.61

704

1Un

ited

King

dom

4.46

322

45.

1794

24

5.17

942

46.

6045

24

Unite

d St

ates

of A

mer

ica22

.000

01

822

.000

01

822

.000

01

822

.000

01

8

TOTA

L UN

ITS

5153

5355

REVI

SED

SCAL

E fo

r 201

8-20

19 P

ROPO

SED

BUDG

ETSC

ALE

for 2

012-

2013

APP

ROVE

D BU

DGET

Info

rmat

ion

Tabl

e D

GROU

P CL

ASS

IFIC

ATI

ON O

F CO

UNTR

IES

AND

ASS

IGNI

NG U

NITS

FOR

ASS

ESSE

D CO

NTRI

BUTI

ONS

From

201

2 to

201

9

Parti

cipat

ing

Stat

e

GROU

P A

ND U

NIT

ASS

IGNE

D TO

EA

CH P

ART

ICIP

ATI

NG S

TATE

SCAL

E fo

r 201

6-20

17 A

PPRO

VED

BUDG

ETSC

ALE

for 2

014-

2015

APP

ROVE

D BU

DGET

GROU

P CL

ASS

IFIC

ATI

ON O

F CO

UNTR

IES

AS

PER

RESO

LUTI

ON G

C/15

/R9


Appr

oved

Bu

dget

20

16-2

017

Units

2018

-201

9%

in

crea

seIn

crea

se

Amou

ntUn

its20

18-2

019

%

incr

ease

/ de

crea

se

Amou

nt

Incr

ease

/ (d

ecre

ase)

Aust

ralia

1,73

7,46

12

1,77

2,31

62.

0134

,855

21,

792,

324

3.16

54,8

6320

,008

Aust

ria1,

494,

554

11,

517,

184

1.51

22,6

301

1,52

7,19

12.

1832

,637

10,0

07Be

lgiu

m1,

494,

554

11,

517,

184

1.51

22,6

301

1,52

7,19

12.

1832

,637

10,0

07Br

azil

1,73

7,46

12

1,77

2,31

62.

0134

,855

21,

792,

324

3.16

54,8

6320

,008

Cana

da1,

737,

461

21,

772,

316

2.01

34,8

552

1,79

2,32

43.

1654

,863

20,0

08De

nmar

k1,

494,

554

11,

517,

184

1.51

22,6

301

1,52

7,19

12.

1832

,637

10,0

07Fi

nlan

d1,

494,

554

11,

517,

184

1.51

22,6

300

1,26

2,05

2-1

5.56

(2

32,5

02)

(255

,132

)ch

ange

from

gro

up 4

to 5

Fran

ce2,

223,

275

42,

282,

580

2.67

59,3

054

2,32

2,60

14.

4799

,326

40,0

21Ge

rman

y2,

223,

275

42,

282,

580

2.67

59,3

054

2,32

2,60

14.

4799

,326

40,0

21In

dia

1,49

4,55

41

1,51

7,18

41.

5122

,630

11,

527,

191

2.18

32,6

3710

,007

Irela

nd1,

251,

647

01,

262,

052

0.83

10,4

050

1,26

2,05

20.

8310

,405

0Ita

ly2,

223,

275

42,

282,

580

2.67

59,3

052

1,79

2,32

4-1

9.38

(4

30,9

51)

(490

,256

)ch

ange

from

gro

up 2

to 3

Japa

n3,

194,

903

83,

303,

110

3.39

108,

207

83,

383,

151

5.89

188,

248

80,0

41M

oroc

co0

01,

262,

052

1,26

2,05

20

1,26

2,05

21,

262,

052

0Ne

ther

land

s1,

494,

554

11,

517,

184

1.51

22,6

301

1,52

7,19

12.

1832

,637

10,0

07No

rway

1,49

4,55

41

1,51

7,18

41.

5122

,630

11,

527,

191

2.18

32,6

3710

,007

Qata

r1,

251,

647

01,

262,

052

0.83

10,4

050

1,26

2,05

20.

8310

,405

0Re

publ

ic of

Kor

ea1,

494,

554

11,

517,

184

1.51

22,6

302

1,79

2,32

419

.92

297,

770

275,

140

chan

ge fr

om g

roup

4 to

3Ru

ssia

n Fe

dera

tion

1,73

7,46

12

1,77

2,31

62.

0134

,855

21,

792,

324

3.16

54,8

6320

,008

Spai

n1,

737,

461

21,

772,

316

2.01

34,8

552

1,79

2,32

43.

1654

,863

20,0

08Sw

eden

1,49

4,55

41

1,51

7,18

41.

5122

,630

11,

527,

191

2.18

32,6

3710

,007

Switz

erla

nd1,

494,

554

11,

517,

184

1.51

22,6

301

1,52

7,19

12.

1832

,637

10,0

07Tu

rkey

1,49

4,55

41

1,51

7,18

41.

5122

,630

11,

527,

191

2.18

32,6

3710

,007

Unite

d Ki

ngdo

m2,

223,

275

42,

282,

580

2.67

59,3

054

2,32

2,60

14.

4799

,326

40,0

21Un

ited

Stat

es o

f Am

erica

3,19

4,90

38

3,30

3,11

03.

3910

8,20

78

3,38

3,15

15.

8918

8,24

880

,041

TOTA

L42

,913

,599

5345

,073

,300

5.03

2,15

9,70

151

45,0

73,3

005.

032,

159,

701

0

Incr

emen

tal

Incr

ease

/(de

crea

se)

from

cur

rent

to

revis

ed s

cale

Chan

ge in

cou

ntry

gro

up

class

ifica

tion

Info

rmat

ion

Tabl

e E

COM

PARI

SON

OF A

SSES

SMEN

TS O

N PA

RTIC

IPA

TING

STA

TES

BASE

D ON

CUR

RENT

AND

REV

ISED

SCA

LES

(exp

ress

ed in

eur

os)

PART

ICIP

ATIN

G ST

ATE

Prop

osed

Bud

get 2

018-

2019

dist

ribut

ed b

ased

on

the

sam

e sc

ale

used

in 2

016-

2017

Bud

get

Prop

osed

Bud

get 2

018-

2019

dist

ribut

ed

base

d on

the

revis

ed s

cale


Leve

l 2Le

vel 2

Obj

ectiv

esRE

GULA

R BU

DGET

ARY

RESO

URCE

SIn

crea

se/(

Decr

ease

) fro

m 2

016-

2017

Leve

l 3Le

vel 3

Obj

ectiv

es S

taff

Budg

et

2018

-201

9

Non

-sta

ff Bu

dget

20

18-2

019

Tot

al20

18-2

019

Sta

ff Bu

dget

N

on-s

taff

Budg

et

Tot

al %

Cha

nge

1De

scrib

e th

e oc

curr

ence

of c

ance

r

1.1

Impr

ove

and

expa

nd re

porti

ng o

f des

crip

tive

canc

er s

tatis

tics

1,89

1,81

5

18

0,00

0

2,07

1,81

5

11

1,93

81,

000

112,

938

5.77

1.2

Supp

ort i

mpr

oved

cov

erag

e an

d qu

ality

of c

ance

r reg

istra

tion,

par

ticul

arly

in lo

w a

nd m

iddl

e-in

com

e co

untri

es (L

MIC

)67

7,06

1

190,

000

86

7,06

1

18,3

440

18,3

442.

16

1.3

Impr

ove

tum

our c

lass

ifica

tion

to in

form

can

cer r

egist

ratio

n, re

sear

ch a

nd tr

eatm

ent

462,

517

10

6,00

0

568,

517

17

6,63

329

,000

205,

633

56.6

7

3,03

1,39

3

47

6,00

0

3,50

7,39

3

30

6,91

530

,000

336,

915

10.6

3

2Un

ders

tand

the

cau

ses

of c

ance

r

2.1

Iden

tify

the

risk

fact

ors

for h

uman

can

cer t

hrou

gh th

e co

nduc

t of e

pide

mio

logi

cal s

tudi

es6,

294,

795

872,

800

7,

167,

595

142,

383

-31,

200

111,

183

1.58

2.2

Eluc

idat

e m

echa

nism

s of

car

cinog

enes

is th

roug

h th

e co

nduc

t of l

abor

ator

y st

udie

s2,

406,

002

419,

400

2,

825,

402

-531

,913

-218

,600

-750

,513

-20.

99

2.3

Prov

ide

expe

rt ev

alua

tions

of t

he a

vaila

ble

evid

ence

-bas

e to

iden

tify

hum

an c

arcin

ogen

s1,

598,

737

280,

000

1,

878,

737

62,1

8812

3,20

018

5,38

810

.95

10,2

99,5

34

1,57

2,20

0

11

,871

,734

-3

27,3

42-1

26,6

00-4

53,9

42-3

.68

3Ev

alua

te a

nd im

plem

ent

canc

er p

reve

ntio

n an

d co

ntro

l str

ateg

ies

3.1

Enha

nce

unde

rsta

ndin

g of

inte

rven

tions

for c

ance

r pre

vent

ion

and

cont

rol

2,22

0,64

7

45

5,00

0

2,67

5,64

7

14

3,15

5-1

06,5

0836

,647

1.39

3.2

Enha

nce

the

impl

emen

tatio

n of

can

cer p

reve

ntio

n an

d co

ntro

l pro

gram

mes

1,07

7,23

1

12

3,00

0

1,20

0,23

1

-1

75,6

0232

,000

-143

,602

-10.

69

3.3

Prov

ide

expe

rt ev

alua

tions

of t

he a

vaila

ble

evid

ence

-bas

e in

ord

er to

reco

mm

end

prev

entio

n st

rate

gies

476,

225

13

5,00

0

611,

225

77

,994

95,8

0017

3,79

439

.73

3,77

4,10

3

71

3,00

0

4,48

7,10

3

45

,547

21,2

9266

,839

1.51

4In

crea

se t

he c

apac

ity fo

r ca

ncer

res

earc

h

4.1

Incr

ease

hum

an re

sour

ces

for c

ance

r res

earc

h72

4,57

1

1,03

0,00

0

1,

754,

571

22,3

7810

0,00

012

2,37

87.

50

4.2

Deve

lop

new

met

hodo

logi

es fo

r can

cer r

esea

rch

3,28

8,51

3

39

8,20

0

3,68

6,71

3

76

1,74

444

,200

805,

944

27.9

8

4.3

Prov

ide

the

reso

urce

s an

d in

frast

ruct

ure

to s

uppo

rt an

d en

hanc

e re

sear

ch3,

117,

425

2,97

2,59

4

6,

090,

019

317,

296

4,33

832

1,63

45.

58

7,13

0,50

9

4,

400,

794

11,5

31,3

03

1,10

1,41

814

8,53

81,

249,

956

12.1

6

5Pr

ovid

e st

rate

gic

lead

ersh

ip a

nd e

nhan

ce t

he im

pact

of t

he A

genc

y’s

cont

ribut

ion

to g

loba

l can

cer

rese

arch

5.1

Defin

e th

e vis

ion

and

impl

emen

t the

scie

ntifi

c st

rate

gy o

f the

Age

ncy,

pro

vidin

g th

e fra

mew

ork

for t

he fu

lfilm

ent o

f its

obj

ectiv

es80

9,08

0

550,

000

1,

359,

080

74,7

890

74,7

895.

82

5.2

Over

see

the

stra

tegi

c di

rect

ion

of th

e Ag

ency

and

the

impl

emen

tatio

n of

its

prog

ram

me

179,

701

21

9,00

0

398,

701

6,

510

06,

510

1.66

5.3

Crea

te a

nd m

aint

ain

key

stra

tegi

c pa

rtner

ship

s w

ith n

atio

nal,

regi

onal

and

inte

rnat

iona

l org

aniza

tions

467,

675

15

0,00

0

617,

675

19

2,78

60

192,

786

45.3

7

5.4

Effe

ctive

ly co

mm

unica

te a

nd d

issem

inat

e th

e w

ork

of th

e Ag

ency

1,88

3,28

9

54

2,00

0

2,42

5,28

9

68

,407

068

,407

2.90

3,33

9,74

5

1,

461,

000

4,80

0,74

5

34

2,49

20

342,

492

7.68

6En

able

and

sup

port

the

eff

icie

nt c

ondu

ct a

nd c

oord

inat

ion

of r

esea

rch

6.1

Ensu

re th

e Ag

ency

is d

irect

ed a

nd m

anag

ed a

ccor

ding

to h

ighe

st s

ecto

r sta

ndar

ds6,

605,

583

1,79

0,51

6

8,

396,

099

200,

688

-53,

010

147,

678

1.79

6.2

Inve

st s

trate

gica

lly to

war

ds in

crea

sing

IARC

’s ca

pacit

y30

3,92

3

175,

000

47

8,92

3

-30,

237

0-3

0,23

7-5

.94

6,90

9,50

6

1,

965,

516

8,87

5,02

2

17

0,45

1-5

3,01

011

7,44

11.

34

TOTA

L34

,484

,790

10

,588

,510

45

,073

,300

1,

639,

481

20,2

201,

659,

701

3.82

Info

rmat

ion

Tabl

e F

COM

PARI

SON

OF P

ROPO

SED

REGU

LAR

BUDG

ET 2

018-

2019

WIT

H A

PPRO

VED

REGU

LAR

BUDG

ET 2

016-

2017

BY

LEVE

L 2/

3 OB

JECT

IVES

(exp

ress

ed in

eur

os)


Information Table G PRIORITY PROJECTS REQUIRING ADDITIONAL VOLUNTARY CONTRIBUTIONS

1. Global Initiative for Cancer Registry Development (GICR) Project Tree Path: 1.2.1

Project summary

Demographic transitions are projected to place the greatest future burden of cancer in LMICs. To mitigate the impact, effective evidence-based cancer control programmes are needed. High-quality population-based cancer registries (PBCR), the basis from which to plan, implement and monitor such programmes, are established in less than one-third of all LMICs. Led by the Agency, the GICR is a collaboration with key international partners to accelerate improvements in the coverage, quality and use of PBCRs worldwide to better inform cancer control.

The GICR aims to contribute to the development of in-country capacity for cancer surveillance through structured support to PBCRs. Coordinated by IARC, six IARC Regional Hubs serve as a first point of contact to provide technical training, consultancies through site visits, mentorship and analysis to produce scientific and policy reports. The GICR represents an expansion of activities that have been, and remain, a cornerstone of the Agency since its inception, yielding cancer indicators and fostering descriptive epidemiologic research.

Resource Gap

The total resource gap for the GICR project during the biennium 2018–2019 is approximately €5.98 million. The GICR Secretariat at IARC has overall responsibility for coordinating activities, ensuring progress and communicating with stakeholders, together with providing technical support to the Regional Hubs and target countries. To support these functions during the biennium 2018–2019, €1.64 million for core infrastructure costs and operations of the Hubs is requested. Additional funding mechanisms will be mobilized from other sources to support the country-led surveillance plans over the period, amounting to €4.34 million.

Expected deliverables in 2018–2019 (conditional on available resources)

• Agreements to provide measurable improvements in the coverage, quality and national networking capacity of cancer registries in at least 20 LMIC;

• Transition of a centralized training and support model to one which is devolved into regions through the expanded presence of the six IARC Hubs;

• Launch of a best practices portal and the production of e-learning tools tailored to support PBCRs in LMIC.

These activities will have major impact in targeted LMICs in terms of an increase in the numbers of qualified registry staff working in PBCRs and improvement of the quality of the data on cancer. Ultimately the GICR will increase the accessibility of robust cancer data for national health care planning, monitoring and evaluation, as well as ensure valid national estimates of cancer burden are publicly available.



2. IARC Monographs Programme Project Tree Path: 2.3.1

Project summary

The IARC Monographs Programme was created in 1971 with the overall aim of providing authoritative, up-to-date evaluations of agents and exposures that present carcinogenic hazards to humans. The hazards that may be evaluated include chemical, physical and biological agents, occupational exposures, complex mixtures, foods, drugs and personal habits. About 1000 such agents have been evaluated to date. The Monographs are respected as a definitive international reference for cancer hazard evaluation. The results are disseminated worldwide and are used by national and international health agencies to support actions to control exposure to known and suspected carcinogens. The Programme’s objective of identifying the causes of cancer is directly relevant to the Agency’s core mission.

Resource Gap

The Monographs Programme is developing a more quantitative approach to hazard evaluation based on advice from a 2014 Advisory Group. Selected Monographs for agents with an adequate database will include quantitative risk estimates within the limits of published data.

To support this approach, the Monographs Section will recruit a scientist with expertise in quantitative exposure assessment. This individual will have operational responsibility for the section covering exposure data in each Monograph, including: managing exposure databases; supporting expert Working Groups in finding and analysing pertinent exposure data and reviewing and fact-checking draft reports. Adding a staff scientist with expertise and responsibilities dedicated to exposure assessment will support the use of quantitative approaches. Along with gains in efficiency, this expansion of the scientific staff together with investment in an additional half-time scientific editor will shorten the time interval from the conclusion of an evaluation to the publication of the final Monograph. The total cost of the additional 1.5 posts is approximately €0.42 million for the biennium.


The activities of the new staff members would be fully integrated with the overall goals of the programme, which has the following major deliverables for the biennium:

• Convene 5 evaluation meetings with Monograph Working Groups; • Convene an Advisory Group on Priorities to review agents for possible future evaluations; • Publish 6 Monograph volumes.

This request supports ongoing efforts to diversify the funding base for the Monographs programme. Currently, the programme relies on approx. €0.88 million of extrabudgetary resources per year in addition to funds from the regular budget. In view of the worldwide impact of the Monographs and their centrality to IARC’S mission, it is a high priority to expand beyond the single large grant that currently supports a significant proportion of the costs for staff and programme operations.



3. Multicentric study of cervical cancer screening and triage with human papillomavirus testing (ESTAMPA)

Project Tree Path: 3.1.2

Project Description

ESTAMPA is an international effort in Latin America to implement organized HPV-based cervical screening and reduce cervical cancer mortality among women in the region, by evaluating emerging screening techniques that can be used to triage HPV positive women and different approaches to implement organized HPV-based screening in the region.

Approximately 50 000 women aged 30–64 years will be HPV-screened in 10 countries in Latin America. The study will provide important data to define triage methods to select women who require further evaluation or treatment among those who are HPV positive, in order to maximize impact of the screening process avoiding excessive diagnostic workup and overtreatment. This will increase the feasibility of the programmes in LMICs. The implementation research components of the study will guide the introduction of HPV-based programs in the region, and the creation of an extensive network of cancer investigators throughout Latin America is expected to lead to new initiatives to develop research in the region. All these activities are fully in line with IARC’s principles and objectives.

Resource Gap

The overall study budget for 2016–2020 is €15 million which is funded mainly from several grants from public funding agencies in the participating countries, the Reproductive Health Research Program of WHO, a grant from the US National Cancer Institute, the UICC and PAHO, as well as from in-kind contributions of the local governments and universities participating in the study. The additional contribution mentioned below will accelerate the programme, including the evaluation of new biomarkers and approaches for cervical cancer control and consolidate the wide network of investigators in the region.

The total voluntary contribution required during the period 2018–2019 to complete the planned activities is €2 million.


• Consolidation of data and biospecimen bank for evaluation of cervical cancer screening and triage methods

• Realization of field work for sub-study on psychosocial impact of HPV testing • Evaluation of alternative implementation strategies (e.g., invitation for self-collection) in selected

study sites • Design of the ESTAMPA prospective cohort study (5 year follow-up)



4. Cancer Screening in Five Continents (CanScreen5) Project Tree Path:

3.2.1

Project summary

CanScreen5 will be a global repository of information on cancer screening programs. The project aims to collect, analyze and disseminate information on the characteristics, performance and effectiveness of screening programs worldwide. This will result in improvements in countries in screening programme management and quality assurance, strengthening health information systems, and ultimately to support the collection of screening data and promoting their use informing policy development and research in cancer prevention and early detection.

The methodology will be based on the Agency’s recent experience compiling the European Screening Report on the status of implementation of cancer screening programmes in the EU. The data collection tools and the data management and analysis plan will be further improved to make them more broad based and suitable for different resource settings. An online platform similar to “Cancer Today” in the IARC Global Cancer Observatory will be developed, to disseminate results in a manner suitable for policy makers, programme managers and researchers.

Resource Gap

CanScreen5 will be a long term project of the Agency, requiring standardization of data collection and analysis from many countries with different levels of health system organization. The total budget needed to complete the project is estimated at around €3.0 million, with the amount required for the first phase during 2018–2019 estimated at €1.2 million.


• Development of tools and guidelines to collect and share data on screening programmes; • Collection and analysis of data and quantitative information on the protocols, management and

performance of screening programs from at least 50 countries in the first phase; • Developing capacity for data collection on screening programs in the selected countries; • Functioning website for data collection and an online platform for dissemination of information

tailored to the needs of various users.

CanScreen5 will be a powerful tool providing access to standardized, systematically collected data and indicators evaluating the performance of cancer screening programmes, eventually in every country where they exist. In addition, it is expected that the project will have an impact in the countries by providing the tools and encouraging them to improve data collection through the development of the health information system for quality assured cancer screening programs.



5. IARC Handbooks of Cancer Prevention (HCP) Project Tree Path:

3.3.1

Project summary

The IARC Handbooks of Cancer Prevention evaluate what are the effective interventions and strategies in cancer prevention, following the same rigorous process as the Monographs. IARC Handbooks have evaluated chemo-preventive agents, individual strategies, cancer screening, and tobacco control policies. The Handbooks support the WHO Global Action Plan on the Prevention and Control of Noncommunicable Diseases. Availability of an international consensus from an independent, specialized Agency within the UN family provides an authoritative basis for health agencies to plan and implement their preventive strategies, and should facilitate national recommendations and communication with the population at risk. Conducting evidence-based evaluations of primary and secondary interventions and strategies to prevent cancer is central to IARC’s mission.

Resource gap

Since their re-launch in 2014, Handbooks have been scheduled every 18 months on average, with very limited resources, and support from the staff of the Monographs Programme. Our aim is to secure sustainable, long-term funding dedicated to the Handbooks, to build the sustainability of the programme, and increase staff with the aim to publish one Handbook per year.

The total cost of one Handbook is of €0.52 million – the funding required for the biennium 2018–2019 amounts therefore to €1.04 million.

Expected deliverables for 2018–2019 (conditional on available resources)

• Publication of IARC Handbook Vol. 17 on colorectal cancer screening; • Publication of IARC Handbook Vol. 18 (topic to be decided).



6. IARC Fellowship Programme Project Tree Path:

4.1.1

Project summary

For five decades as a core statutory function of the Agency, the Fellowship Programme has contributed to the development of human resources for cancer research worldwide. The main goal of the Programme is to provide training in cancer research in areas relevant to the Agency’s programme. Ultimately, the Fellowship Programme also aims at catalysing the creation of collaborative links between IARC, cancer researchers, and research institutes. Although all countries have been targeted in recent years, a specific focus has been on LMICs.

IARC Postdoctoral Fellowships represent the vast majority of awards through the Programme. This scheme targets early career scientists, offering two-year fellowships uniquely tenable at IARC. Fellows from LMICs can apply for a return grant, supporting the establishment of their research activity in their home country. The Programme also attracts senior visiting scientists through a dedicated Award, to participate in collaborative research projects at the Agency. Finally, short fellowships have also been established in relation with the IARC Summer School.

Resource gap

Funding allocated to the Programme under the proposed regular budget for 2018–2019 is €0.86 million, which will allow the award of 11 two-year Postdoctoral Fellowships over the biennium (this includes the additional extraordinary contribution of €80 000 mentioned under Objective 4 of the Programme). In the past seven years, additional extrabudgetary funding was secured through two consecutive EC MSCA FP7-COFUND grants, complemented with bilateral agreements with Cancer Council Australia and the Irish Cancer Society. The funding from the COFUND programme allowed the award of around eight additional two-year Postdoctoral Fellowships per biennium. In 2015, IARC submitted a new application under the EC MSCA H2020-COFUND-2015 call for which the Agency was deemed ineligible.

The objective being to maintain the number of fellowships awarded, a shortfall of €0.56 million need to be secured over the biennium through alternative sources of funding.


• Eighteen two-year IARC Postdoctoral Fellowships awarded over the biennium;

• Partnerships set up in order to develop additional bilateral Postdoctoral Fellowships;

• Four short-term Fellowships awarded every year;

• Two Senior Visiting Scientist Awards each year.

This additional funding would ensure that the number of training opportunities for early career scientists are maintained, and that IARC can pursue its mission to contribute the development of new generations of cancer researchers, especially in LMICs.



7. IARC “Nouveau Centre” Plus Project Tree Path:

6.1.1

Project summary

The Nouveau Centre is a major building infrastructure project at the core of IARC’s global research mission for the next 30 to 50 years. The new building is an integral part of IARC’s business continuity plan, ensuring building infrastructure security in the long term.

The design and construction phase of the new IARC building, to be located in the Gerland bio-district area of Lyon, is overseen by the Métropole de Lyon in cooperation with other French authorities. The project started in 2011, in close collaboration with local partners, and should be completed in 2021 when IARC moves to its new premises. The budget for the Nouveau Centre core project amounts to €49.26 million (as of July 2016) funded by the French authorities, which covers building costs, and partially covers infrastructure and equipment costs.

Apart from coordinating and assisting the Métropole de Lyon in the daily management of the project, IARC is required to finance and manage the design and installation of offices, meeting rooms and public facilities, the partial renewal of IARC’s scientific equipment, and the physical move to its new premises. IARC will also take advantage of this important opportunity for modernization to create a fully enabling working environment for its personnel. These activities are not covered in the above quoted budget for the Nouveau Centre core project.

Resource gap

The additional costs to fully complete the move and installing IARC in the new premises is conservatively estimated at €7.78 million. IARC management pledged to set aside €1.5 million from overheads earned over the five year period of 2015–2019 to partially cover the physical move. The City of Lyon will provide €1.2 million from sales proceeds of the Latarjet and BRC buildings to be utilized to partially cover office design and installation costs. Residual balance of funds approved by the GC for legal services related to the Nouveau Centre project (Resolution GC/54/R6) and anticipated revenue from sales of old furniture and equipment will further contribute to cover these expenses. Nonetheless, the remaining unfunded balance of €5.04 million will be required to be mobilized over the next five year period of 2017–2021, with a target of €2.52 million for the 2018–2019 biennium.

Expected deliverables (conditional on availability of resources)

• Design and installation of offices, meeting rooms and ITC infrastructure (€0.94 million)

• Strengthened security measures, appropriate public facilities and internal building infrastructure (€0.86 million)

• Newly installed automated biobank and laboratory facilities (€2.70 million)

• Smooth transition and seamless physical move to the new premises (€0.54 million)

proposed programme and budget...

Documents